Thyroid hormones are direct modulators of human hair follicle growth and pigmentation

Inauguraldissertation
zur
Erlangung der Doktorwürde
der Universität zu Lübeck
- Aus der Medizinischen Fakultät -

vorgelegt von Nina van Beek
aus Lübeck

Lübeck 2010
1. Berichterstatter: Prof. Dr. med. Ralf Paus

2. Berichterstatter: Prof. Dr. med Heiner Möning

3. Berichterstatter: Prof. Dr. Dr.-Ing. Jürgen Lademann

Tag der mündlichen Prüfung: 21.03.2011

Zum Druck genehmigt. Lübeck, den 21.03.2011
# TABLE OF CONTENTS

## ABBREVIATIONS

| ABBREVIATIONS | 5 |

## INTRODUCTION

1. **Background**

1.2 **The human hair follicle**

1.2.1 Anatomy

1.2.2 Hair follicle cycling

1.2.3 Endocrine controls of human hair follicle cycling

1.2.4 Hair follicle pigmentation

1.3 **Thyroid hormones**

1.3.1 Thyroid hormones and their metabolism

1.3.2 Neuroendocrine controls of thyroid hormone synthesis

1.3.3 Classical and non-classical signalling of thyroid hormones

1.3.4 Physiological functions of thyroid hormones

1.4 **Cutaneous effects of thyroid hormone abnormalities**

1.4.1 Causes of hypothyroidism and hyperthyroidism

1.4.2 Skin and skin appendage abnormalities associated with hypo- and hyperthyroidism

1.5 **Aim of the study and specific questions addressed**

1.6 **Experimental Design**

## MATERIALS AND METHODS

2. **Hair follicle isolation and organ culture**

2.1.1 Hair follicle sources

2.1.2 Micro dissection of human anagen VI hair follicles

2.1.3 T3 and T4-treatment in hair follicle organ culture

2.1.4 Measurement of hair shaft elongation

2.2 **Quantitative hair cycle and hair pigmentation histomorphometry**

2.3 **Immunohistochemistry**

2.3.1 Ki67/TUNEL

2.3.2 TGFβ2

2.3.3 COX1
2.3.4 EPO ....................................................................................................... 51
2.3.5 CK14.................................................................................................... 52
2.3.6 CK6........................................................................................................ 53
2.4 Quantitative immunohistomorphometry............................................. 53
2.5 RT-PCR: Deiodinases .......................................................................... 54
2.6 Statistical analysis................................................................................... 55

3 RESULTS......................................................................................................... 56

3.1 T4 stimulates human hair matrix keratinocyte proliferation, while both T3 and T4 inhibit apoptosis of these cells ......................... 56
3.2 T3 and T4 do not significantly alter human hair shaft structure formation in vitro ................................................................................ 58
3.3 Both T3 and T4 prolong anagen duration ............................................. 60
3.4 TGFβ2 immunoreactivity is down-regulated by thyroid hormones...... 62
3.5 T3 and T4 differentially modulate follicular keratin expression ........ 64
3.6 T3 and T4 stimulate hair follicle pigmentation ................................... 66
3.7 Thyroid hormones enhance follicular erythropoietin immunoreactivity 68
3.8 Cytochrome-c-oxidase subunit 1 (COX1) immunoreactivity is up regulated by T3 and T4................................................................. 70
3.9 Deiodinases types 2 (D2) and 3 (D3) are transcribed by human HFs.... 72

4 DISCUSSION .............................................................................................. 73

5 SUMMARY .................................................................................................. 88

6 ZUSAMMENFASSUNG ............................................................................... 89

7 REFERENCES .............................................................................................. 91

7.1 Publications ............................................................................................. 105
7.2 Danksagung ............................................................................................ 106
7.3 Curriculum Vitae ..................................................................................... 108
Abbreviations

ABC = Avidin-biotin complex
ACTH = adrenocorticotrope hormone
AP = Alkaline phosphatase
ATP = adenosine triphosphate
bcl-2 = B-cell lymphoma 2 protein
BM = Basement membrane
BMP = Bone morphogenetic protein
cAMP = Cyclic adenosine monophosphate
cGMP = Cyclic guanosine monophosphate
CK = Cytokeratin
COX1 = cytochrome-c-oxidase subunit 1
CRH = corticotropin releasing hormone
CRH-R = corticotropin releasing hormone receptor
CTS = Connective tissue sheath
CT = Cuticle
CutL 1 = transcription factor
DAPI = 4′,6′-diamidino-2′-phenylindol-dihydrochloride
DHT = dihydrotestosterone
DIO = Deiodinase
DIT = diiodinated tyrosine
DNA = Deoxyribonucleic acid
DOPA = 3,4- dihydroxyphenylalanine
DP = Dermal papilla
ECM = Extracellular matrix
eSC = Epithelial stem cell
EPO = erythropoietin
Fig = Figure
FITC = Fluorescein isothiocyanate
FOXN1 = Forehead box N1
HCl = Hydrochloric acid
HF = Hair follicle
RXR = Retinoid-X-receptor
rT3 = reverse T3
SCF = Stem cell factor = c-kit
SEM = Standard error of the mean
SG = Sebaceous gland
Shh = Sonic hedgehog
SW = Sweat gland
Tab = Table
TBG = thyroid binding globulin
TBS = Tris buffered saline
TdT = Terminal dioxynucleotidyltransferase
TG = thyreoglobulin
TGF-β1 = Transforming growth factor-β 1
TGF-β2 = Transforming growth factor-β 2
TH = thyroid hormones
TNT = Tris buffered saline add triton-x
TPO = thyroid peroxidase
TR = thyroid receptors
TRE = thyroid hormone response element
TRH = thyreotropin releasing hormone
TSA = thyramide signal amplification
TSH = thyreotropin = thyroid stimulating hormone
TUNEL = terminal dUTP nick-end labelling
T3 = triiodothyronine
T4 = tetraiodothyronine (L- thyroxine)
α-MSH = alpha- melanocyte stimulating hormone = melanotropin
6BH4 = L-erythro 5,6,7,8 tetrahydrobiopterin
Figures

**Figure 1.2** The human hair follicle in anagen VI .......................................................... 13
**Figure 1.3** The anagen VI HF and its associated structures ........................................... 14
**Figure 1.4** HF development and cycling ........................................................................... 18
**Figure 1.5** Hormonal controls of HF-cycling ..................................................................... 22
**Figure 1.6** Structure of thyroid hormones ......................................................................... 27
**Figure 1.7** Control and feedback regulation of thyroid hormone production along the HPT axis ........................................................................................................ 29
**Figure 1.8** Nuclear action of thyroid hormones ................................................................. 30
**Figure 2.1** Hair follicles in culture well plate and scheme ................................................ 43
**Figure 2.2** Illustration of microdissection of human anagen VI hair follicles, organ culture and deep-freezing ....................................................................................... 46
**Figure 2.3** HF in different stages (see Kloeppe et al. 2009) ................................................. 47
**Figure 2.4** reference region for Ki67-/TUNEL staining ....................................................... 50
**Figure 2.5** reference areas for evaluation of the different stainings ................................... 54
**Figure 3.1** T4 stimulates human hair matrix keratinocyte proliferation and both T3 and T4 inhibit hair matrix keratinocyte apoptosis ......................................................... 56
**Figure 3.2** Apoptosis and proliferation of TH-treated HFs ................................................ 57
**Figure 3.3** Hair shaft elongation and morphology ............................................................... 59
**Figure 3.4** Both T3 and T4 prolong anagen duration .......................................................... 61
**Figure 3.5** Histomorphometry of TGF-β2 immunoreactivity (IR) ....................................... 63
**Figure 3.6** Differential effect of TH on human hair keratin protein expression in situ ............................................................................................................................ 65
**Figure 3.7** T3 and T4 stimulate the hair follicle pigmentation ............................................ 67
**Figure 3.8** Thyroid hormones enhance follicular erythropoietin immunoreactivity (IR) in situ ........................................................................................................................................ 69
**Figure 3.9** Cytochrome-c-oxidase immunoreactivity is stimulated by T3 and T4 ................. 71
**Figure 3.10** Micro dissected human anagen VI hair follicles express deiodinases type 2 (D2) and 3(D3)................................................................................................................. 72

Tables

**Table 1.1** Basic data on human hair .................................................................................. 11
**Table 1.2** Trichology terms ................................................................................................ 16
**Table 1.3** Some factors involved in the control of HF cycling ........................................... 20
**Table 1.4** Examples for tissue effects of thyroid hormones .............................................. 33
**Table 1.5** Human HF in hypo- and hyperthyroidism .......................................................... 38
**Table 2.1** Thyroid status of all patients, whose HFs were examined .................................... 42
**Table 2.2** Scheme of HF treatment in organ culture .......................................................... 45
**Table 2.3** Criteria for classification of HF in anagen and different stages of catagen ................................................................. 47
**Table 2.4** Primary antibodies used and reference tissues employed as positive controls ............................................................................................................................ 49
**Table 4.1** different pathways of thyroid function ............................................................... 84
1 Introduction

1.1 Background

Since thyroid hormones (TH) provide crucial endocrine controls for human development and metabolism (see below), it is not surprising that TH also affect human skin. TH abnormalities are commonly associated with changes in hair follicle (HF) appearance and function. It has long been observed that prominent hair abnormalities in patients with thyroid dysfunction occur (Freinkel and Freinkel 1972, Messenger 2000, Schell et al. 1991, Ebling 1991). In addition, several in vivo-studies have demonstrated that thyroid hormones (TH) exert potent hair-growth modulatory effects e.g. in sheep, rats and mice (Safer et al. 2001, Hale and Ebling 1979, Ferguson 1965). However, these effects are partially conflicting, since application of thyroxine (T4) increased the weight of wool grown in adult sheep (Ferguson 1965), thus indicating a growth promoting effect, while in rats application of thyroxine only shortened anagen but did not stimulate hair growth (Hale and Ebling 1979).

Figure 1.1 Hair loss in thyroid disease

In humans, diffuse loss of scalp hair follicles, body hair and the lateral eyebrows are clinical signs associated with hypothyroidism, along with the presentation of dry, brittle and dull hair shafts (Freinkel and Freinkel 1972, Schell et al. 1991, Ebling 1991). Confusingly hyperthyroid states can also lead to effluvium, despite an apparently increased hair matrix proliferation (Schell et al. 1991). Hyperthyroid HFs produce a thinner hair shaft diameter and brittle, greasy hair (Messener 2000, Fistarol 2002) and display substantially reduced tensile strength (Stüttgen 1974, Everett et al. 1997). Also, early greying has been claimed to be related to autoimmune thyroid disease, hypothyroidism and non-autoimmune
hyperthyroidism (Kaminski 1997, Lerner 1971), while darkening of gray hair has recently been reported in a few patients after TH administration (Redondo et al. 2007).

The HF is a continuously remodelling and regenerating mini organ, which undergoes phases of massive proliferation (anagen), apoptosis-driven organ involution (catagen), and relative resting (telogen) during hair follicle cycling (Chase 1954, Paus et al. 2000, Schneider et al. 2009). The structure of the HF and its hair shaft is subject to numerous controls, including a very large variety of hormones, growth factors, cytokines and neuropeptides (Paus and Cotsarelis 1999, Stenn and Paus 2001, Dawber 2006, Ohnemus et al. 2006, Schneider et al. 2009). Therefore, it is not surprising that changes in HF structure and hair growth can be important clinical signs of underlying endocrine abnormalities, such as hyperandrogenism, Cushing syndrome, ectopic ACTH production and hyperprolactenemia. Furthermore hormonal treatment can exert substantial hair growth-modulatory affects (e.g. in patients treated with antiandrogens, L-thyroxine, retinoids, or antiestrogens) (Zouboulis et al. 2007, Foitzik et al. 2005, Deplewski & Rosenfield 2000, Paus et al. 2007).

Although the phenomenon of TH-induced hair growth alterations has been appreciated for many decades (Sainton and Simonnet 1931, Rook 1965, Freinkel and Freinkel 1972, Stüttgen 1974), the underlying mechanisms are still very incompletely understood. In particular, it remains to be conclusively documented that TH really exert direct effects on human HFs and the yet unclear mechanisms of triiodothyronine (T3) and tetraiodothyronine (T4) affecting human hair shaft formation, HF cycling, HF pigmentation and hair keratinisation. While human scalp HFs do express TH receptors (Billioni et al. 2000, Ahsan et al. 1998), it is not clear whether the clinical hair growth abnormalities seen in patients with thyroid disease reflect direct effects of TH or are the consequence of secondary endocrine abnormalities, e.g. the up-regulation of serum thyroid stimulating hormone (TSH) levels - a defining feature of hypothyroidism (Sawin et al. 1985), or thyroid disease-associated changes in the serum insulin level (Velija-Asimi and Karamelic 2007, Dimitriadis et al. 2006).
<table>
<thead>
<tr>
<th><strong>BASIC DATA OF HUMAN HAIR FOLLICLES</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total number</strong></td>
</tr>
<tr>
<td><strong>Number of scalp hair follicles</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Average density (scalp) terminal + vellus</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Highest density: cheek + forehead</strong></td>
</tr>
</tbody>
</table>

- **Hair embryology**
  - Development progresses at fixed intervals (274-350 µm) in cephalocaudal direction, becoming first visible in eyebrow, upper lip and chin region (9th week).
  - At 16 weeks, hair shafts are formed in these regions.
  - Hair follicles are formed in sequential waves of inter-related follicles.

- **Hair cycle distribution**
  - Anagen: 85-90%
  - Catagen: 5-10%
  - Telogen: ~ 10%

- **Duration of hair cycle phases**
  - Anagen: 2-6 years
  - Catagen: 2-3 weeks
  - Telogen: 3 months
  - There are substantial variations in anagen duration.
  - **Terminal moustache**: 6-14 weeks
  - **Terminal arms**: 6-12 weeks
  - **Terminal legs**: 19-20 weeks
  - **Vellus**: 6-12 weeks
  - Premature anagen induction induced by plucking of telogen hair shafts (depilation)
  - Estrogens prolong anagen.
  - Thyroxine promotes growth, corticosteroids retard anagen onset.

- **Number of lifetime cycles**
  - 10-20

- **Physiological hair shedding rate (scalp)**
  - ~ 100-200/day (substantial interindividual and seasonal variations)

- **Hair shaft production rate (scalp)**
  - ca 0.35 mm/day, 1 cm/month
  - Hair production is not influenced by cutting/shaving.
  - Estrogens reduce hair growth rate.
  - Androgens increase hair growth rate and hair diameter in androgen-dependent sites (beard).

- **Hair shaft diameter and length**
  - Vellus: <0.03 mm, 1-2 mm
  - Terminal: > 0.06 mm, 1 mm
  - Average diameter:
    - Mongoloid hair (circularly): 120 µm
    - Caucasian (elliptically): 50-90 µm

- **Hair shaft structures**
  - Cuticle (outside), cortex, medulla (center)
  - Cuticle maintains hair fiber integrity.
  - Cortex contains bulk of hair keratins and keratin-associated proteins.
  - Hair fiber strength is largely due to disulfide bonding.
  - Medulla consists of loosely connected trichocytes with large intercellular air spaces; provides insulation (animals).

- **Hair shaft pigmentation**
  - Dark hair: predominance of eumelanin
  - Blond hair: pheomelanin predominates
  - Melanosomes of hair cortex larger than those of epidermis.

- **Hair greying (canities)**
  - Generally commences in the third decade of life on the temples, spreading later to crown and occiput; by the age of 50 years, 50% of the population has at least, 50% grey hair.

- **Hair patterns**
  - Public hair: (90% of women, 20% of men)
  - Axillary hair: (10% of women, 50% of men)
  - Pubic hair: normally grows only in men, from puberty (1st to 6th decade)
  - Armpits appear about 2 years after first pubic hairs, more sparse in Mongoloids than Caucasians; frequently absent in older individuals.
  - Keloids: single, clockwise parietal whirl present in 95% of individuals.

---

**Table 1.1 Basic data on human hair**
To address the direct effects of hormones on the human follicle in vitro, one can study scalp hair follicles that have been surgically removed from any confounding systemic (neural, vascular) influences and that are organ-cultured under serum-free conditions in the presence of insulin and hydrocortisone (Philpott et al. 1990 & 1996, Foitzik et al. 2005 & 2006, Conrad et al. 2005). Therefore, normal, micro dissected and organ-cultured human scalp HFs are ideally suited to study the human hair growth response to stimulation with TH.

In order to fully appreciate the multiple effects that hormones can exert on hair growth and pigmentation, it is necessary to recapitulate some basic elements of hair follicle biology.

1.2 The human hair follicle

1.2.1 Anatomy

The human HF is an epidermal derived, largely epithelial mini organ, which operates under the control of a highly specialized fibroblast population of mesenchymal origin (i.e. the follicular dermal papilla [DP]). The DP is onion-shaped and contains these densely packed fibroblasts that display inductive and morphogenic properties even in the adult organism (Paus and Cotsarelis 1999, Schneider et al. 2009). The DP is located in the proximal part of the HF and changes its shape and location dependent on the state of hair follicle cycling (see below) (Handjiski et al. 1994). By the number and profound secretory capacities of its fibroblasts the DP determines the size of the hair bulb and, thereby, the diameter of the hair shaft as well as the duration of anagen (Reynolds et al. 1999, Paus 2008, Schneider et al. 2009) (Fig.1.2).

The epithelial part of the HF is composed out of several, concentrically arranged layers of specialized keratinocytes that surround the hair shaft in its centre. The outermost layer of the HF epithelium, the outer root sheath (ORS), is in direct contact and grows in continuitatem with the epidermis. The ORS, in turn, is enwrapped by the HF’s connective tissue sheath (CTS), which – like the DP - is also derived from the mesoderm and connects the HF and to its surrounding skin compartments (dermis, subcutis) (Paus and Cotsarelis 1999, Schneider et al. 2009).
The HF can be viewed as a multicylindric structure serving as a hair fibre production facility and that guides the directional growth of that hair fibre onto the skin surface. This hair fibre (hair shaft) usually is composed out of a central medulla, around which a cortex and cuticle are arranged. The cuticle is the outermost layer of the hair shaft, is responsible for its shine, and maintains hair shaft integrity (Powell and Rogers 1997). The cortex contains hair keratins and keratin-associated proteins as well as trichocytes aligned to the hair shaft axis and the cuticle (Table 1.1). The medulla consists of loosely connected trichocytes and connecting proteins (Powell and Rogers 1997).

**Figure 1.2 The human hair follicle in anagen VI**
A) schematic overview, B) proximal HF in skin
The hair shaft is surrounded by the cuticle of inner root sheath (IRS), which is then covered by Huxley’s layer and finally Henle’s layer, thus completing the IRS as a guiding structure for the extruded central hair shaft (Fig. 1.2). It moves outwards together with the hair fibre using the companion layer- which might be a part of the outer root sheath (ORS) or an independent cell compartment- as a sheet of drift (Langbein et al. 2002, Stenn and Paus 2001, Gu and Coulombe 2007). The IRS terminates at the level of the sebaceous gland. With the outermost layer of the ORS the eight epithelial layers forming the human HF are completed (Fig. 1.2). Each layer expresses both shared and distinct structural proteins, e.g. keratins (Langbein et al. 2004).

Human terminal HFs can display three main associated structures - the arrector pili muscle, a sebaceous gland and an apocrine gland. These glands empty their specialized products (sebum, apocrine sweat) into the follicular canal via separate ducts that insert into the ORS (infundibulum) (Fig. 1.3). The arrector pili muscle (smooth muscle) allows a variation of the usually oblique angle of hair shafts (Headington 1984). This adrenergically controlled activity of the arrector pili muscle serves thermo-insulatory needs by regulating the amount of air trapped around the associated hair shaft and is involved in reactions to external stressors (Poblet et al. 2002, Paus et al. 2007).

**Figure 1.3 The anagen VI HF and its associated structures**
(Modified after: Paus et al: Biology of hair and nails. In: Bologna et al. (eds), Dermatology, 2007)
The hair bulb is defined as the proximal part of the HF, containing the dermal papilla, matrix keratinocytes and the surrounding parties of IRS and ORS (Fig. 1.3). In terminal anagen HFs (see below), the hair bulb is situated in the subcutaneous tissue. The anagen hair bulb can be considered the actual “hair shaft factory”, since it contains the very rapidly proliferating hair matrix keratinocytes which when reaching the area above the dermal papilla, differentiate to trichocytes forming the hair shaft (Powell and Rogers 1997, Paus et al. 2007, Cotsarelis and Botchkarev 2008).

Like the HFs of all other mammals, the human HF can be structured into different compartments. At the site of insertion of the arrector pili muscle into the ORS, one finds the bulge region (Fig. 1.3), which is the major seat of follicular epithelial stem cells (Oshima et al. 2001, Ohyama et al. 2006, Cotsarelis 2006). Epithelial stem cells are identified by their very slow-cycling nature and strong expression of keratin 15 and 19 as well as of CD 200 (Oshima et al. 2001, Ohyama et al. 2006, Cotsarelis 2006, Kloeppep et al. 2008). These stem cells appear to reside within an immunologically privileged tissue niche (Meyer et al. 2008).

Between the insertion of the arrector pili muscle and the infundibulum of the sebaceous gland the isthmus region, characterized by a particularly dense sensory and autonomous innervation and numerous Merkel cell complexes (Paus et al., 1997), is located (Fig. 1.3). This makes the human HF a highly sensitive tactile organ being able to detect the slightest touch brought about by HF movements. In addition to these sensory and motor functions, the follicular neural plexus might also have important regulatory potential in releasing neurotransmitters, neuropeptides and neutrophins (Paus et al. 1997, Botchkarev et al. 1998, Botchkarev et al. 2000, Botchkarev et al. 2004).

The nutrition of the HF is largely provided by the dermal and subcutaneous vascular plexus that ensheath the entire HF. They form rich, basket-like structures of arterioles, capillaries and venules with numerous shunts situated in the CTS. This vascular plexus inserts into the dermal papilla of terminal hair follicle and ensures access to nutrients, oxygen, regulatory molecules and hormones and allows excretion of toxic metabolites (Sakita et al. 1994, Mecklenburg et al. 2000, Paus et al. 2007).
Table 1.2 Trichology terms


Human HF can be grouped into three major, different types of hair: lanugo hair, vellus hair and terminal hair. **Lanugo hair** is the fine hair produced by fetal skin.
HF, which is shed during the first weeks of life or in utero. Vellus hair (ca. 4.9 million HF) (Mohn 1958) can be defined as usually non-medullated, non-pigmented, without an arrector pili muscle and very short. Vellus hair follows the full hair follicle cycle. Terminal hair (about 100,000 HF) is the familiar hair type of the scalp and is characterised by the presence of a medulla, long length and pigmentation (Paus and Cotsarelis 1999, Vogt et al. 2007, Schneider et al. 2009) (Tab. 1.2). In human scalp skin, 2 to 4 terminal and 1 to 2 vellus hair follicles are organized in a so-called “follicular unit” sharing one arrector pili muscular structure (Poblet et al. 2002).

### 1.2.2 Hair follicle cycling

The human HF undergoes life-long cyclic regression and regeneration dictated by an autonomous molecular oscillator system known as the “hair cycle clock” (Paus and Foitzik 2004), which induces controlled switches in the local signalling milieu that drive the HF through major remodelling events (Paus et al. 2007, Paus and Cotsarelis 1999). However, the exact location (DP or HF epithelium) and the molecular nature of this “hair cycle clock” is still unclear. In addition, a second, extra follicular oscillator system has recently been discovered in the dermis and subcutis of murine skin which impacts on and possible entrains the intra follicular, dominant “hair cycle clock” (Plikus et al., 2008, Plikus and Chuong, 2008). Whatever controls this unique cycling mechanism, which is without parallel in mammalian biology, is responsible for driving not only HF remodelling, but also controls the major vascular, pigmentary, neuronal, matrix and connective tissue remodelling events that are tightly coupled to human HF cycling (Stenn and Paus 2001, Paus and Foitzik 2004).

The most proximal portion of the HF, the hair bulb, is also called the ‘cycling portion’ since it displays the most dramatic morphological changes during each hair cycle. The ‘permanent portion’ is formed by the epithelial stem cell-containing bulge region, which also harbours melanocyte stem cells (Nishimura et al. 2002, Aoki et al. 2009), the isthmus, the infundibulum and the follicular ostium with its canal. It shows no dramatic remodelling, although substantial remodelling takes place during each hair cycle even in the ‘permanent portion’, as well (Lindner et al. 1997).
During these cyclic transformations greatly disparate length, the HF passes through eight stages of catagen (catagen I-VIII), i.e. the apoptosis-driven involution phase of HF cycling. These are followed by telogen, the resting phase, and six stages of anagen (anagen I- VI), the growth phase, before the HF re-enters into catagen. The subcategories of the phases (Fig. 1.4) were established and characterized in murine hair follicles (Chase 1954, Müller-Röver et al. 2001), but also apply to the human HF (Kligman 1959, Kloepfer et al. 2009).

**Figure 1.4  HF development and cycling**


**Catagen** is characterized by apoptosis, terminal differentiation and rapid organ involution. Apoptosis, also known as programmed cell death, occurs primarily in defined apoptotic foci, namely in the hair matrix, the proximal and central ORS and
in melanocytes, but not in the dermal papilla, where high levels of bcl-2 expression appear to suppress apoptosis (Lindner et al. 1997, Müller-Röver et al. 2000). During catagen the HF shrinks and its DP condenses, in part due to the emigration of DP fibroblasts into the proximal CTS (Tobin et al. 2003). The proximal follicle epithelium regresses to a sac-like epithelial strand, above which the club hair forms. The club hair has a characteristic brush-like proximal tip, and is anchored to the secondary hair germ (Fig. 1.4). The club hair is depigmented at its proximal end, because this portion is generated during late catagen, i.e. at a time when melanogenesis has already ceased (Slominski et al. 1994, Slominski et al. 2005). The process of normal catagen development is highly controlled on several molecular levels. In this control, the zinc finger structure hairless gene (Hr) is one essential coordinator, which guarantees that apoptosis occurs in the right compartments and in the right sequence. In absence of functional Hr-protein (hr) the HF is destroyed during the first time it enters catagen, leading to the characteristic naked skin phenotype of the hairless mutation in mice, rats, or humans (Panteleyev et al. 2000, Paus and Foitzik 2004, Schneider et al. 2009).

**In telogen** biochemical and proliferative activity decline to a minimum compared to the other phases in HF-cycling, even though the HF is less “quiescent” than often assumed during this “resting phase”. In fact, telogen may serve as a crucial ‘brake on anagen’ and therefore have major regulatory importance in hair cycle control (Paus et al. 2000, Stenn and Paus 2001, Paus et al. 1990, Paus and Foitzik 2004, Schneider et al. 2009).

**Anagen** is marked by massive epithelial cell proliferation in the hair matrix and by an enlargement of the bulb and its DP, not the least due to the immigration of fibroblasts from the CTS into the DP (Tobin et al. 2003, Schneider et al. 2009). Anagen partly recapitulates key morphological aspects HF development, and the HF re-uses some of the same key modulatory factors that drive HF-morphogenesis (e.g. IGF, HGF, KGF; BMP2, TGFβ2, NT3; see table 1.3). The first sign of anagen termination is a retraction of melanocytic dendrites along with a shut-down of melanogenesis (Slominski et al. 1994 & 2005).
<table>
<thead>
<tr>
<th>Modulatory factor (examples)</th>
<th>Reference</th>
<th>Effect</th>
<th>Hair cycle phase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Noggin</strong></td>
<td>Botchkarev et al., 2001</td>
<td>Signal from DP to epithelial stem cells (ESC)</td>
<td>anagen</td>
</tr>
<tr>
<td><strong>STAT3</strong></td>
<td>Sano et al., 2000</td>
<td>Required for anagen onset</td>
<td>telogen</td>
</tr>
<tr>
<td><strong>KGF</strong></td>
<td>Rosenquist and Martin, 1996</td>
<td>Signal from DP to epithelium, induction of anagen</td>
<td>anagen</td>
</tr>
<tr>
<td><strong>SHH</strong></td>
<td>Wang et al., 2000</td>
<td>Epithelial proliferation</td>
<td>anagen</td>
</tr>
<tr>
<td><strong>IGF-1</strong></td>
<td>Philipott et al., 1994</td>
<td>Epithelial proliferation, anagen maintenance</td>
<td>anagen</td>
</tr>
<tr>
<td><strong>CutL 1</strong></td>
<td>Ellis et al., 2001</td>
<td>Differentiation of inner root sheath</td>
<td>anagen/exogen</td>
</tr>
<tr>
<td><strong>Cathepsin L</strong></td>
<td>Tobin et al., 2002</td>
<td>Causing exogen</td>
<td>anagen/exogen</td>
</tr>
<tr>
<td><strong>BMP</strong></td>
<td>Botchkarev and Paus, 2003</td>
<td>Differentiation of HS</td>
<td>anagen</td>
</tr>
<tr>
<td><strong>FOXN1</strong></td>
<td>Johns et al., 2005</td>
<td>Differentiation of HS</td>
<td>anagen</td>
</tr>
<tr>
<td><strong>TGFβ2</strong></td>
<td>Hibino and Nishiyama, 2004</td>
<td>Catagen induction</td>
<td>anagen/catagen</td>
</tr>
<tr>
<td><strong>NT3</strong></td>
<td>Botchkarev et al., 1998</td>
<td>Catagen induction, growth modulator during morphogenesis</td>
<td>anagen/catagen</td>
</tr>
<tr>
<td><strong>p75NTR</strong></td>
<td>Botchkarev et al., 2000</td>
<td>Catagen induction</td>
<td>anagen/catagen</td>
</tr>
<tr>
<td><strong>Prolactin</strong></td>
<td>Foitzik et al., 2006</td>
<td>Catagen induction</td>
<td>anagen/catagen</td>
</tr>
<tr>
<td><strong>INFγ</strong></td>
<td>Ito et al., 2005</td>
<td>Inhibition of hair elongation, catagen induction (partly via TGFβ2)</td>
<td>anagen/catagen</td>
</tr>
<tr>
<td><strong>IL-1</strong></td>
<td>Lindner et al., 1998</td>
<td>Catagen induction</td>
<td>anagen/catagen</td>
</tr>
<tr>
<td><strong>Hr</strong></td>
<td>Panteleyev et al., 2000</td>
<td>Key catagen controller</td>
<td>catagen</td>
</tr>
</tbody>
</table>

**Table 1.3 Some factors involved in the control of HF cycling**

During cycling a new hair shaft factory has to be constructed in each anagen phase. In the bulge region, as the known epithelial and melanocyte stem cell reservoir (Tiede et al. 2007), bulge epithelial stem cells are mainly responsible for reconstruction of the anagen ORS, whilst the IRS, hair matrix and hair shaft keratinocytes may arise from a distinct stem cell population in the secondary hair germ, which is located between the DP and telogen club hair (see below) and
which persists throughout HF cycling (Paus and Foitzik 2004). However bulge epithelial stem cells can generate all epithelial cell lineages (Cotsarelis 2006).

Hair shaft shedding (termed “exogen”) is the process of active hair shaft removal from the follicular canal. Exogen is linked to HF cycling, but not dependent upon it (Stenn and Paus 2001, Higgins et al. 2009). Therefore it is not a component of basic hair follicle cycling. While a new hair shaft is built up, the former hair shaft is shed, possibly during anagen IV. Cathepsine L, a lysosomal cysteine protease, appears to be involved in the control of exogen (Tobin et al. 2002, Schneider et al. 2009) (Table 1.3). If HFs malfunction or threaten to degenerate, they can be eradicated permanently by a process that has been coined “programmed organ deletion” (POD). This irreversible immunodestruction of the HF by an auto aggressive inflammatory cell infiltrate may diminish damage which could be caused by a malfunctioning HF, e.g. by protrusion of the hair shaft into the dermis, rather than its extrusion to the skin surface (Eichmüller et al. 1998).

These signalling interactions result in a special local balance of stimulating and inhibitory factors for each single HF that is responsible for its cyclic transformations. And that markedly differs between defined HF subpopulations in distinct regions of the integument (Paus and Cotsarelis 1999, Schneider et al. 2009). These interregional differences are most obvious in the “paradoxical” effects of androgens, which stimulate e.g. the growth of male beard HFs, but inhibit that of fronto- temporal male and female scalp HFs (Randall 2007, Zouboulis et al. 2007). Recent evidence suggests that estrogens and prolactin also exert important site- and/or gender-specific regulatory effects on human hair follicle growth (Conrad et al. 2005, Langan et al. 2009).

Although HF cycling is essentially independent of functional innervation and blood supply (Maurer et al. 1998, Philpott et al. 1996), substantial remodelling of the HF’s vasculature and innervation occurs during each HF cycle and both neural and vascular inputs can modulate HF cycling (Mecklenburg et al. 2000, Paus and Foitzik 2004).

1.2.3 Endocrine controls of human hair follicle cycling

Despite its essentially autonomous growth regulation, the HF is highly sensitive to alterations in systemic endocrine signalling, e.g. by androgens (Randall 2007,
Zouboulis et al. 2007), estrogens (Ohnemus et al., 2006), and prolactin (Foitzik et al. 2009, Langan et al. 2009). This may serve to coordinate and synchronize the activities of larger cohorts of HFs, e.g. in response to environmental or nutritional changes (Yen 2001).

Though androgens have long been viewed as the main regulators of human hair growth (Randall 2007), the importance of other endocrine controls of human hair growth is being increasingly appreciated (e.g. Ohnemus et al. 2006, Foitzik et al. 2009) (Fig. 1.5).

![Hormonal influence on human scalp hair follicles](image)

**Figure 1.5 Hormonal controls of HF-cycling**

Selection of important hormones involved in HF-cycling and homeostasis. *Prolactin: catagen induction in occipital male scalp HFs (Foitzik et al. 2006), but catagen inhibition in female front temporal HFs (Langan et al. 2009).*

In addition, the HF and its associated sebaceous gland are becoming increasingly appreciated as astoundingly active producers and metabolizers of a wide range of different hormones, ranging from sex steroids and prolactin, via erythropoietin (Bodó et al. 2007a) and endocannabinoids to all key endocrine mediators of the hypothalamic-pituitary-adrenal axis (HPA: CRH→POMC→ACTH→cortisol) (Telek et al. 2007, Foitzik et al. 2006).
Centrally released, systemically active mediators of general stress responses are e.g. corticotrophin releasing hormone (CRH), adrenocorticotrope hormone (ACTH), β-endorphin, prolactin (PRL) and catecholamines (Fig. 1.5). CRH is secreted by the hypothalamus to stimulate the HPA axis resulting in secretion of glucocorticoids. These ensure an adaptive response to restore homeostasis of human HF but also suppress immune response (Slominski et al. 2007). As an extra pituitary site of PRL- synthesis (Foitzik et al. 2006) and expressing both PRL and PRL receptors (PRL-R) human anagen VI HFs utilize PRL as an autocrine hair growth modulator with catagen-promoting functions and hair growth-inhibitory effects.

While the central role of androgens in hirsuitism and androgenic alopecia constitutes a central paradigm of clinical trichology, androgens are actually dispensable for fetal HF development and for HF cycling as such. Individuals who lack functional androgen receptors still develop vellus hair and have largely normal scalp hair (Dawber 1997). However, androgens do regulate mostly sexual aspects of hair with “paradoxical” effects, depending on the body site: a comparison of beard growth and balding shows the complex interactions between local signalling milieu (see above) and hormonal influence on the whole organism (Paus et al. 2007). Thus, a rise in systemic androgen levels during puberty is crucial for inducing the vellus-to-terminal transformation of androgen-dependent (i.e. beard, axillary and pubic) HFs. These “paradoxical” effects of androgens probably reflect very different responses of a given hair follicle population to androgen stimulation (e.g. secretion of hair growth promoting IGF-1 versus hair growth-inhibitory TGFβ1 by DP fibroblasts after exposure to androgens (Itami and Inui 2005).

It is on this background of complex, and often seemingly contradictory, endocrine controls of human HF cycling that the current study on the effects of TH on human HF growth, cycling, and pigmentation has to be interpreted.

1.2.4 Hair follicle pigmentation

The pigmentation of human HFs is tightly coupled to the anagen phase of the HF cycle (Slominski et al. 2005). In the anagen hair bulb, the melanocytes essential for hair pigmentation are situated within the hair matrix epithelium, on the basement membrane surrounding the dermal papilla, where they form the HF
pigmentary unit (HPU). These specialized, differentiated HF melanocytes transfer melanin to pre-cortical keratinocytes (Michelet et al. 2009). Two classes of melanins are generated: eumelanin, and phaeomelanin. Eumelanins are “polyquinones” organized in polymers that are synthesized from tyrosine and DOPA (3,4-dihydroxyphenylalanine). Phaeomelanins are smaller biopolymers than eumelanins and also derive from tyrosine. The relative predominance of eumelanin versus phaeomelanin determines the visible hair colour. Besides by the quality and quantity of its melanins, the resulting hair colour also is influenced by the thickness of the hair shaft (Slominski et al. 2005).

Melanogenesis represents a very complex biochemical cascade of events that is restricted to specialized organelles (melanosomes) and is regulated by a multitude of different factors and co-factors, ranging from transcription factors, via enzymes to hormones, cytokines, neuropeptides and adhesion molecules (Yamaguchi and Hearing 2009, Park et al. 2009). Follicular melanogenesis is initiated by hydroxylation of L-phenylalanine to L-tyrosine by phenylalanine hydroxylase (PAH) (Schallreuter et al. 1998, Slominski et al. 2005). The key enzyme for melanogenesis is tyrosinase, which requires the presence of copper and oxygen for its catalytic activity. Tyrosinase catalyzes the hydroxylation of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-dopa). Once L-dopa is formed, melanogenesis can proceed through redox reactions and intra-molecular transformations (Slominski et al. 2005).

The melanoblasts migrate from the neural crest, enter the developing HF and as precursors expressing c-kit they migrate into the stem cell factor (SCF)-supplying hair follicle epithelium (Peters et al. 2002). These melanocytes are maintained by small numbers of melanocyte stem cells located at the HF stem cell niche- the bulge region (Nishimura et al. 2002, Aoki et al. 2009, Sarin and Artandi 2007,). The differentiated, c-kit-positive melanocytes populate the hair bulb (Peters et al., 2002), whose epithelium produces the c-Kit ligand, SCF (Peters et al. 2003). C-kit-negative melanoblasts preferentially target the ORS and the bulge region in the HF. Furthermore, c-kit is required during the hair growth cycle for activation of HF pigmentary unit melanocytes during anagen III-VI (Botchkareva et al. 2001), when active melanin synthesis accompanied by massive tyrosinase activity occurs (Slominski et al. 2005).
The melanocytes of the HF are larger than epidermal melanocytes, develop longer dendrites, but contact fewer keratinocytes than epidermal melanocytes (Scott et al. 2002). As the normally only site of pigment production for the hair shaft the bulb contains highly melanogenic melanocytes, a few less differentiated pigment cells and amelanotic hair bulb melanocytes. Transfer of melanin granules to cortical and medullary keratinocytes in the growing hair shaft has been explained by the extension of filopodia from melanocyte dendrites. This dendrite formation acts as a transporter device for melanosomes towards the keratinocytes (Scott et al. 2002 & 2007, Aspengren et al. 2009). Thus, melanocyte dendriticity is an important phenotypic aspect of melanin transfer to keratinocytes. Furthermore melanin synthesis and transfer depend on the availability of melanin precursors and several receptor-dependent and receptor-independent signalling pathways (Tobin 2008, Park et al. 2009).

The produced melanosomes are only minimally digested by keratinocytes, mainly those of the hair cortex, and therefore stain the hair shaft in its full length (Slominski et al. 2005). Melanogenically active melanocytes are restricted to the precortical hair matrix of the anagen hair follicle from where melanosomes are transferred to the hair shaft cortex, and much less to the medulla and cuticle. To ensure renewed hair shaft pigmentation during each new anagen cycle, the activated hair germ stimulates resident, dormant melanocytes to divide in and populate the new anagen hair bulb (Nishimura et al. 2002, Aoki et al. 2009, Slominski et al., 2005).

HF-melanogenesis is highly influenced by several different hormones and cytokines, both stimulatory and inhibitory ones. α-MSH, β-endorphins, histamine, prostaglandins, catecholamines as well as estrogens, androgens and vitamin D enhance the follicular melanogenesis using different second messenger pathways. In contrast, serotonin, melatonin, acetylcholine and dopamine acting via its D2 receptor display an inhibitory effect on melanogenesis. These factors are thought to be essential for the “fine-tuning” of HF pigmentation (Slominski et al. 2004, Park et al. 2009, Tobin 2008). Most recently, even TH have become implicated as a potential regulatory element in hair pigmentation (Redondo et al. 2007), even though it remains unknown whether THs can directly alter human HF pigmentation.
1.3 Thyroid hormones

1.3.1 Thyroid hormones and their metabolism

The thyroid gland contains follicular (epithelial) cells for hormone synthesis. Several follicular cells form a follicle wherein the thyroid hormone can be stored as colloid (Dunn and Dunn 1999). The very complex system of thyroid hormone (TH) synthesis, storage and release is sharply controlled by feedback regulation as well as other regulatory mechanisms to ensure that the healthy thyroid gland is always capable of releasing the necessary amount of TH that is required to maintain systemic/metabolic homeostasis (Molina 2006, Singer 2009).

For TH synthesis, a sodium-iodide symporter (NIS) in the basolateral membrane of thyroid follicular epithelial cells guarantees an energy-dependent iodide uptake. In the apical membrane of these cells lie at least two iodide channels, one of which is called pendrin (Everett et al. 1997, Bizhanova and Kopp 2009), allowing iodide efflux into the follicular lumen. Here the glycoprotein thyroglobulin (TG), containing several tyrosine residues, functions as a matrix for TH-generation and serves as the main part of the colloid at the same time (Dunn and Dunn 1999). The follicular epithelial cells produce TG in a thyrotropin (TSH)-dependent manner and secrete it mainly into the follicular lumen but also in small amounts into the peripheral blood circulation (Fekete and Lechan 2007). Strikingly, TG transcripts have recently even been found in human scalp hair follicles (Bodó et al. 2009b).

In the thyroid follicle lumen, iodide is oxidated to iodine by thyroid peroxidase (TPO), a glycoprotein located at the apical membrane (Kopp 2005). This step relies on the presence of H$_2$O$_2$ as a rate-limiting factor. H$_2$O$_2$ is regenerated in active thyroid follicular epithelium by thyroid oxidase type 1 and 2 (THOX1, THOX2) (Gérard et al. 2002), contingent on calcium availability and hydrogenated nitrogenamide-adenine-dinucleotide phosphate (NADPH). Then TPO serves as an essential tool for coupling iodine to the tyrosine residues of TG at carbon 3 or 5. The iodination yields monoiiodinated (MIT) and diiodinated (DIT) tyrosine residues that are enzymatically united to triiodothyronine = T3 (DIT + MIT) or
tetraiodothyronine = T4 (DIT + DIT) by thyroid peroxidase (Fig.1.6). The generated T3 and T4 can be stored in the colloid for 2-3 months (Nilsson 2001).

![Figure 1.6 Structure of thyroid hormones](image)

These conjugated residues while still bound to TG undergo endocytosis, the formed vesicles fuse with follicular epithelial phagolysosomes in which digestion and cleavage of TG takes place. TG and non conjugated MIT and DIT are reused in hormone synthesis after transportation in the colloid while T3 and T4 are released into the circulation at the basal membrane of the thyroid follicular cell (Nilsson 2001, Molina 2006).

The thyroid gland releases less T3 compared to T4, leading to a higher plasma concentration of T4 (ca. 90nM) compared to T3 (ca. 2nM) (Molina, 2006). T4 serves as a prohormone for T3 and is converted by 5’ outer ring deiodination to T3, mainly in the liver but to some extent in all peripheral tissues investigated so far. T4 has a 100 times lower affinity to the thyroid hormone receptor than T3. T4 binds more tightly to binding proteins: both TH are mainly bound to thyroid-binding globulin (TBG) but also to transthyretin and albumin. Only 0.3% of T3 and 0.03% of T4 occur in their free form in human blood. Additionally, T4 has a longer biological half-life of 7 days than T3 (1 day) since only free TH are excreted by the kidneys (Bizhanova and Kopp 2009).

About 80% of T4 are deiodinated in the periphery, while most of the deiodinase activity yields active T3 (33% yield reverse T3 [rT3] with little or no TH activity) (Molina 2006). By further deiodination rT3 and T3 are converted to the biologically inactive T2, although recent studies suggest a role of T2 in rat fat metabolism (Lanni et al. 2005). For deiodination, different deiodinases (DIO) are required, whose expression patterns differ between tissues. DIO 1 is expressed predominantly in liver, kidney and thyroid and catalyzes conversion of T4 to T3/rT3.
and T3/ rT3 to T2 and is important for the feedback mechanism. Type 2 DIO has only outer ring deiodination activity and converts T4 to T3. It provides more than 50% of the T3 used in brain, brown adipose tissue, cardiac and skeletal muscle. It is also active in thyroid and pituitary where it is necessary for feedback regulation of TSH secretion. DIO 3 only displays inner ring function thus inactivating T4 to rT3 and T3 to T2. It is mainly expressed in brain, placenta and skin (Köhrle 1999, Safer et al. 2009). Intriguingly, DIO2 has been found to be transcribed by human bulge HF epithelial stem cells in situ (Ohyama et al. 2006, Tiede et al. 2009), which suggests that these stem cells can actively deiodinate T4 into T3.

1.3.2 Neuroendocrine controls of thyroid hormone synthesis

TH synthesis and release are tightly regulated by the hypothalamic-pituitary-thyroid axis (HPT-axis) (Larsen et al. 2007, Fekete and Lechan 2007, Singer 2009). At the hierarchical top of this regulatory axis, thyrotropin releasing hormone (TRH), is synthesized in the paraventricular nucleus of the hypothalamus. Then, TRH is released via the median eminence of the hypothalamus. Here nerve endings lead the TRH into the portal capillary plexus which passes the capillary system of the anterior pituitary gland (Fekete and Lechan 2007). TRH binds to G\textsubscript{q}-cell membrane receptors (TRH-R) on basophilic cells of the anterior pituitary gland. The resulting activation of phospholipase C and the generation of inositol triphosphate and diacylglycerol raises the intracellular calcium concentration, which serves as the stimulus for exocytosis and release of thyroid-stimulating hormone (TSH) into the systemic circulation (Fekete and Lechan 2007).

TSH binds to a G-protein coupled receptor at the baso-lateral membrane of follicular epithelial cells of the thyroid. Via second messenger pathways, the intracellular cyclic adenosine monophosphate (cAMP) concentration increases whereby TSH provokes a stimulation of all steps involved in thyroid hormone synthesis (e.g. iodine uptake, storage, release, cell proliferation, protection from apoptosis). TSH- and TRH-release underlie negative feedback regulation (Fig. 1.7) by T3 and T4. T4 is converted to T3 mainly peripherally but also in the hypothalamus and anterior pituitary to T3 by type 2 deiodinase. Therefore TSH-release underlies at least a dual inhibition directly via circulating T3 and T4, and
indirectly through inhibition of TRH-release (Shupnik et al. 1989). In addition, dopamine, somatostatine and glucocorticoids at high levels are also potent partial suppressors of TSH-release (Yen 2001, Molina 2006).

**Figure 1.7 Control and feedback regulation of thyroid hormone production along the HPT axis**

TRH = thyreotropin releasing hormone, TSH = thyreotropin or thyroid stimulating hormone, T3 = triiodothyronine, T4 = thyroxine, =inhibition, text written in green = stimulation

In the context of HF biology, this HPT axis (Singer 2009) has recently become particularly relevant, since it was shown that human scalp HFs express TRH, TRH- and TSH- receptors (Gáspár et al. 2009, Bodó et al. 2009b) and that TRH is a strong stimulator of human hair growth in organ culture (Gáspár et al. 2009). Therefore, some up-stream elements of the HPT axis also operate in human skin, thus making the "thyroid-skin connection" an even more fascinating and clinically relevant research frontier in cutaneous (neuro-)endocrinology (Paus 2010).

**1.3.3 Classical and non-classical signalling of thyroid hormones**

TH primarily exert nuclear hormone receptor-dependent genomic effects, but also non-genomic TH actions are now recognized (Davis et al. 2008). For their genomic action, TH enter the cell via carrier-dependent, energy-dependent or Na⁺-dependent processes. They enter the nucleus and bind to thyroid hormone receptors (TR) of which several isoforms exist (TRα1, TRα2, TRβ1, TRβ2, TRβ3) (Fig. .8). TR are c-erb-A proteins and belong to the nuclear hormones super-family
consisting of thyroid hormone, glucocorticosteroid, retinoic acid, and vitamin D receptors (Aranda and Pascual 2001). TRs bind TH with high affinity and specificity (85% T3, 15% T4), and usually do so in a dimeric form with the retinoid-x-receptor (Moore and Guy 2005). TRs are DNA-binding factors, which, in their unoccupied form, are bound to TH response elements (TRE) in the promoter region of TH target genes where they associated with a couple of co-repressors.

![Figure 1.8 Nuclear action of thyroid hormones](Moore and Guy 2005; A)diagram of the primary structure of the TR subtypes; B) mechanism of TR transcriptional control. TR forms a heterodimer complex with RXR that recognizes specific TREs; AF, activation function; LBD, ligand binding domain; NTD, amino-terminal transactivation domain; T3,triiodothyronine.)

TH binding then leads to co-repressor dissociation and binding of co-activators which results in modulation of the gene transcription (Fig. 1.8).

In contrast to activating TH binding, the TRE can also be negatively regulated (Feng et al. 2000), thus repressing genomic transcription upon ligand binding while the unliganded receptor guarantees a constitutive level of gene transcription. Activation of the nuclear machinery by T3 has a latency of hours or days (Yen 2001). Nevertheless, a number of TH-effects occur rapidly and are unaffected by
inhibitors of transcription and protein synthesis (Wrutniak-Cabello et al. 2001) e.g. T4 inducing IP3 via cytosolic binding on TRβ and calcium signalling, and TH augmentation of the effects of IFNγ via PKC and PKA (Lin et al. 1997). Furthermore cell culture studies indicate a rapid and non-genomic regulation of the Ca2+ATPase enzyme, the Na+ channel via PKC, the K+ channel via PI3-kinase, the Na+/H+ anti-porter via PKC and MAPK by thyroid hormones (Davis et al. 2008). The activation of MAPK suggests a G-protein coupled membrane receptor for thyroid hormones involved, of which the activation via several steps leads to phosphorylation of a serine residue one of the zinc finger structures in TR resulting in increased transcriptional activity (Davis et al. 2008).

In parallel to these fast-acting signalling pathways, T4 was also shown to activate MAPK- kinase (MEK), which phosphorylates tyrosine residues in signal transducers and activators of transcription (STAT1α and STAT3), thus inducing both, the nuclear translocation of both STAT, and further serine phosphorylation by MAPK (Lin et al. 1999). Using these messenger pathways, TH are able to potentiate antiviral or immunomodulatory effects of IFNγ (Lin et al. 1999). Such non-genomic effects of TH have been reported in several tissues, e.g. T4 displaying rapid thermogenic and lipolytic activities or T3 enhancing cardiac output and reducing systemic vascular resistance within 3 minutes via catecholamines, since the action of T3 could be blocked by the β-catecholamine- receptor antagonist esmolol (Schmidt et al. 2002). However, no specific G-protein coupled membrane receptor binding any isoform of TH could be identified so far.

1.3.4 Physiological functions of thyroid hormones

TRs are expressed in all tissues, although the relative expression level of TR isoforms may vary among tissues. In addition, the functional role and relative importance of TH varies greatly between different tissues (Yen 2001). Generally, the TH-induced transcription of Na⁺-/K⁺-ATPase leads to increased oxygen consumption, but the transcription of uncoupling protein enhances heat generation without adenosine triphosphate (ATP) production (Yen 2001). TH- regulated, protein synthesis and degradation contributes to growth and differentiation. Furthermore TH are crucial for several developmental processes. One of the most impressive examples is amphibian metamorphosis, which depends on TH (Paris et
al. 2008), while hypothyroidism in neonate humans seems to be associated with a damage of axonal growth of various brain cells (e.g. cerebellum) and a decrease in IQ (Gyamfi et al. 2009). In the fact, the appearance of TH during evolution may have constituted a major developmental landmark, since many of the genes encoding thyroid-associated proteins like TR, TPO, TRH, TSH, NIS and deiodinases all can already be detected in our amphibian ancestors, and have thus been evolutionarily highly conserved. This suggests that the development of TH and their signal transduction systems have played an important role in vertebrate evolution (Paris et al. 2008).

TH directly affect cellular energy metabolism, namely the key respiratory chain enzyme mitochondrial cytochrome-c-oxidase (Mutvei and Nelson, 1989, Sheehan et al. 2004, Pillar and Seitz 1997). Cytochrome-c-oxidase (also known as complex IV of the mitochondrial respiratory chain) is responsible for the catalyzation of the transfer of four electrons to molecular oxygen. Thereby dioxygen (O$_2$) is reduced to water. Simultaneously, the enzyme pumps protons across the inner membrane of mitochondria from the matrix to the cytoplasmic side. This process is essential for the oxidative phosphorylation catalyzed by Complex V, the last complex at the inner membrane of mitochondria, resulting in the production of adenosine triphosphate (ATP) (Arnold et al. 1998).

Cytochrome-C-oxidase consists of three subunits, the mitochondrial encoded subunits I and II execute the electron transfer function of the holoenzyme while the nuclear encoded subunit III might modulate the proton pumping and/or is involved in the assembly and stability of the mitochondrial encoded subunits (Mutvei and Nelson 1989). Since cytochrome-c-oxidase seems to be a rate limiting enzyme (Sheehan et al. 2004), it is intriguing to ask whether an effect of T3 and/ or T4 on cytochrome-c-oxidase can be verified in human HFs, since this would likely indicate a major impact of TH on human HF energy metabolism.

TH also display several tissue-specific effects (Table 1.4). For example, in the cardiovascular system, TH have an inotropic and chronotropic effect and decrease the systemic vascular resistance; together, this leads to an increase in cardiac output (Yen 2001). Moreover TH enhance total protein expression in the heart, especially of those proteins that are critical for cardiac function such as myosin
heavy chain (Dillmann 1990). Furthermore, in fat, intracellular lipid accumulation and adipocyte proliferation is reduced by TH, and TH increase the number of β-adrenoreceptors on adipocytes, thus promoting catecholamine-mediated lipolysis. TH metabolites can furthermore reduce cholesterol level, and increase lipid metabolism (Moreno 2008). In the liver, TH is involved in triglyceride and cholesterol metabolism and modulates cell proliferation and mitochondrial respiration, while in brain it stimulates the axonal growth of nerve cells. TH are among the essential factors of a normal brain development. (Oppenheimer and Schwartz 1997, Gyamfi et al. 2009). TH is critical for normal bone growth and development. TH increases alkaline phosphatase activity and osteocalcin expression in osteoblasts as well as it affects osteoclasts (Gouveia et al. 2002). TH may act on bone via TH stimulation of growth hormone and insulin-like growth factor I (IGF-I) or by direct effects on target genes (Yen 2001).

<table>
<thead>
<tr>
<th>Tissue affected</th>
<th>TH- effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>heart</td>
<td>Increased cardiac output</td>
<td>Yen 2001, Schmidt et al. 2002</td>
</tr>
<tr>
<td></td>
<td>Enhanced myosin heavy chain synthesis</td>
<td>Dillmann 1990</td>
</tr>
<tr>
<td>fat</td>
<td>Reduction of cholesterol levels by TH derivatives</td>
<td>Moreno et al. 2008</td>
</tr>
<tr>
<td>Vascular system</td>
<td>Lowered systemic vascular resistance</td>
<td>Schmidt et al. 2002</td>
</tr>
<tr>
<td>brain</td>
<td>Development</td>
<td>Oppenheimer and Schwartz 1997</td>
</tr>
<tr>
<td></td>
<td>Axonal growth</td>
<td>Gyamfi et al. 2009</td>
</tr>
<tr>
<td>bone</td>
<td>Increased turnover</td>
<td>Gouveia et al. 2002</td>
</tr>
<tr>
<td>Various tissues</td>
<td>Up regulation of EPO-expression</td>
<td>Ma et al. 2004, Bodó et al. 2007a</td>
</tr>
<tr>
<td></td>
<td>Enhanced expression of COX1 in mitochondria</td>
<td>Sheehan et al. 2004</td>
</tr>
</tbody>
</table>

*Table 1.4 Examples for tissue effects of thyroid hormones*

Intriguingly, T3 has been reported to up-regulate erythropoietin (EPO) expression in a hepatic epithelial cell line *in vitro* (Ma et al. 2004). EPO is a glycoprotein that essentially works as a cytokine. EPO responds to a fall in partial oxygen pressure
(p O₂) in arterial blood, renal EPO-secretion occurs and enhances erythropoiesis in bone marrow. The putative T3-regulation of EPO maybe relevant in the context of this thesis project, since it was recently identified that human scalp HFs are an important extrarenal source and a non-classical, non-hematopoietic target of EPO (Bodó et al. 2007a, Paus et al. 2009). Hypoxia even up-regulates intrafollicular EPO expression (Bodó et al. 2007a). EPO activates the erythropoietin receptor (EPO-R), which inhibits the pro-apoptotic machinery of EPO-R expressing target cells, induced by changes in gene expression (Jelkmann 2004). EPO suppression of apoptosis is not restricted to erythropoietic cells but is also observed in several other tissues – including human HFs (Bodó et al. 2007a). Thus, EPO may serve as a cell-protectant which may protect cells, for example, against ischemia-induced apoptosis. Moreover, it has been hypothesized that the skin itself is able to directly contribute to the up-regulation of EPO plasma levels in response to hypoxia (Paus et al. 2009)

### 1.4 Cutaneous effects of thyroid hormone abnormalities

#### 1.4.1 Causes of hypothyroidism and hyperthyroidism

Hypothyroidism can be defined as insufficient TH action with low serum levels of free T4 often along with elevated TSH-levels (Molina 2006). One has to distinguish between primary and secondary hypothyroidism. The primary form results from a disease of the thyroid gland. It might be due to congenital hypothyroidism accompanied by mental retardation and cretinism or to dietary iodine deficiency as well as iatrogenic thyroid gland destruction (e.g. due to radioactive iodine therapy for autoimmune thyroiditis or thyroid carcinoma). Autoimmune thyroid disease, is most prominently represented by Hashimoto thyroiditis (Hashimoto 1912; due to auto antibodies against TPO and/or TG, which can result in hypothyroidism. Typically, the serum TSH-level is high in this case, while T3 can be low or normal in serum (Pearce et al. 2002, Singer 2009)

Secondary hypothyroidism is caused by disorders in the anterior part of the pituitary gland or the hypothalamus leading to an impaired TSH-release (e.g. due to neoplasia in hypothalamus or pituitary gland) and therefore a lack of stimulation
thyroid gland by TSH. TSH, T3 and T4 serum levels, here, are decreased. Some of the patients show TH- resistance, mostly due to a thyroid receptor-β mutation, which is a rare, inherited lower responsiveness of target tissues to TH. Here TSH-, T3- and T4- levels are high, probably as a compensatory mechanism to reach a nearly euthyroid state (Paschke and Ludgate 1997, Fekete and Lechan 2007).

Hyperthyroidism is defined as an excessive functional activity of the thyroid gland with high serum levels of free T3 and free T4. TSH-levels can be low as in the immunogenic form e.g. Grave’s disease (Brent 2008) or M. Basodow, defined as immunogenic hyperthyroidism with exophthalmia (von Basedow 1840) or in non-immunogenic forms like toxic goitre. In Grave’s disease the TSH-receptor gets stimulated by auto antibodies, a stimulatory immunoglobulin G, yielding excessive production of T3 and T4 whilst TSH-production is repressed via the feedback mechanism (Molina 2006, Brent 2008, Kopp 2005). In toxic goitre, autonomous areas that exist physiologically to fight a lack of exogenous iodide intake are enhanced. A severe iodide deficiency yields goitre and finally results in thyroid autonomy (Singer 2009). Rare causes for hyperthyroidism are sub-acute thyroid inflammation, thyroid carcinoma or excessive exogenous TH-substitution. TSH-secreting adenoma as one of the non-immunogenic forms of secondary hyperthyroidism is characterized by high TSH-serum levels, since the feedback mechanisms outlined above do not work in this case (Larsen et al. 2007, Singer 2009).

1.4.2 Skin and skin appendage abnormalities associated with hypo- and hyperthyroidism

The resulting abnormalities in TH serum levels impact on the function of skin and its appendages, with both similarities and characteristic differences between hypo- and hyperthyroidism. In the skin, hypothyroidism leads to characteristic, clinically detectable changes. Hypothyroid patients typically, though not always, present a pale and cold skin due to cutaneous vasoconstriction, sometimes in association with subcutaneous oedema. The morphological thinning of the epidermis with a thickening of the stratum corneum appears as a coarse, dry and scaly upper skin layer (Table 1.5). In many patients, excessive accumulation of hydrophilic
mucopolysaccharids in the dermis causes a generalized interstitial oedema (myxoedema). This myxoedema can even cause secondary compression complications in the affected region. Furthermore the skin might appear slightly yellow because it suffers from secondary carotenaemia (Fistarol 2002, Stüttgen,1974): TH affects the hepatic transformation of carotene into vitamin A. Therefore, in hypothyroidism there is also a relative hypovitaminosis A (with resulting defects in normal keratinocyte differentiation and epidermal barrier formation), and a higher amount of carotene stays in the circulation. Additionally, hypothyroidism leads to a lessening of eyebrow hair in the lateral third of the eyebrows.

By reason of the systemic effects of TH, like enhanced thermo-generation, heightened cardiac output and raised sweat-production the skin in hyperthyroidism gets warm, soft and moist. Even the thickness of the epidermis is modulated by the T3 serum level, (higher serum-T3 correlates with enhanced epidermal thickness) . Furthermore, at the site of vessels and adnexa haemosiderin deposits can be found in hyperthyroid conditions (Banba et al. 1999). A form of myxoedema that is particularly prominent in the pretibial location can be seen in hyperthyroidism. This myxoedema rather is comparable to the aggregation of mucopolysaccharides in exophthalmia than to myxoedema in hypothyroidism (Fistarol 2002).

Since cytokeratins, which can be grouped into acidic (type I) or basic (type II) keratins, form 30% of the epidermal protein, it is most likely that they are involved in at least some of these changes in human skin due to TH-disorders. Indeed, keratin expression is tightly regulated by various endocrine factors, including THs (Ramot et al. 2009). TH-regulated cytokeratin genes like CK6 and CK14 reportedly display a thyroid hormone responsive element (TRE) in their promoter region via which the transcription of this keratin gene is regulated upon TH binding to TR (Radoja et al. 1997, Freedberg et al. 2001, Blumenberg et al. 1992). As in the rest of the skin epithelium, keratins are also prominently expressed in human HFs, e.g. cytokeratin 6 (CK6, type II) that is typically expressed by proliferating ORS keratinocytes (Langbein and Schweizer 2005), and cytokeratin 14 (CK 14, type I), which is highly expressed by proliferating keratinocytes (Langbein et al. 2004,
Therefore, it is conceivable, but remains to be demonstrated, that TH-induced alterations in HF keratin expression could induce in specific changes in HF-morphology and hair shaft structure (Schweizer et al. 2007).

Hypothyroid patients display HFs that are dry, brittle and dull due to a lower sebum production. 50% of the patients suffer from diffuse alopecia which seems to result from a shorter anagen phase and slower growth. Correlating with the myxoeedema in the dermis the HFs develop mucine concretions. (Fistarol 2002, Molina 2006). The HFs of hyperthyroid individuals show a thin and fine texture and appear fatty. In hyperthyroidism alopecia also occurs but only in 20-40% of patients. This is explained by a shortening of hair cycling with a shortened anagen- and telogen-phase. There is considered to be a shorter final length of the hair due to the shorter growth phase although proliferation in anagen is enhanced (Schell et al. 1991). Clinically, the most important effect that hair growth-inhibitory or -promoting agents can have is to prolong the duration of anagen, or to induce premature catagen development, since this will lead to enhanced hair growth or telogen effluvium, respectively (Paus and Cotsarelis 1999).

Recently Redondo et al. reported darkening of gray/white hair in some patients after TH administration (Redondo et al. 2007). These observations were made after treatment of myxedema coma and in iatrogenic hyperthyroidism with increased exogenous T3, suggesting an influence of the hormone on HF-pigmentation. Before, “early greying” has been claimed to be related to autoimmune thyroid disease, hypothyroidism and hyperthyroidism (Lerner 1971, Kaminski 1997) indicating hormone-regulated changes in hair pigmentation. These hair effects may reflect a modulatory influence of TH on human HF-cycling (Freinkel and Freinkel 1972, Ebling 1991), since hair follicle melanogenesis is strictly coupled to anagen phase. Alternatively, there might also be a direct, hair cycle-independent effect on TH and HF-melanogenesis. However, it still remains to be conclusively shown that TH affects human HF pigmentation at all.
<table>
<thead>
<tr>
<th>Thyroid state</th>
<th>HF- effects</th>
<th>reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypothyroidism</strong></td>
<td>Dry, brittle and dull hair, mucine concretions</td>
<td>Fistarol 2002</td>
</tr>
<tr>
<td></td>
<td>diffuse hair loss</td>
<td>Molina 2006</td>
</tr>
<tr>
<td></td>
<td>Early greying</td>
<td>Kaminski 1997</td>
</tr>
<tr>
<td><strong>Hyperthyroidism</strong></td>
<td>Thin, fine texture and fatty hair, alopecia</td>
<td>Fistarol 2002</td>
</tr>
<tr>
<td></td>
<td>Shortened final length of and growth phase of HF</td>
<td>Schell et al. 1991</td>
</tr>
<tr>
<td></td>
<td>Darkening of grey hair in hyperthyroid state due to treatment with T3</td>
<td>Redondo et al. 2007</td>
</tr>
</tbody>
</table>

**Table 1.5 Human HF in hypo- and hyperthyroidism**

However, multiple endocrine abnormalities can be associated with thyroid dysfunction [e.g. up regulation of serum TSH as a defining feature of primary hypothyroidism (Sawin et al. 1985, Singer 2009) and thyroid disease-associated changes in the insulin serum level (Velija-Asimi and Karamehic 2007, Dimitriadis et al. 2006)]. Therefore, it is not at all clear whether the recognized effects TH on hair growth and/or pigmentation reflect direct alterations of HF functions by TH, rather than indirect HF responses to secondary endocrine abnormalities. However, it has already been convincingly demonstrated that human scalp HF do express TH-receptors on the gene and protein level (TRβ1) (Ahsan et al. 1998, Billoni et al. 2000). In addition, Billoni et al. have reported that T3 prolongs the “survival” of micro dissected, organ-cultured human scalp HF (Billoni et al. 2000), even though it remained unclear what this claim was based on and exactly was meant by it. In any case, this report encourages one to assume that the detected TRβ1 proteins are functionally active in human HFs.

On this background, we have employed micro dissected, organ-cultured human scalp HFs that are grown under serum-free conditions, supplemented with insulin and hydrocortisone (but in the absence of TH!), as a physiologically relevant preclinical test system for probing the effects of TH on human HF growth, cycling, and pigmentation.
1.5 Aim of the study and specific questions addressed

This study is aimed at elucidating whether TH have any direct effect on isolated, organ-cultured human HFs, i.e. in the absence of systemic endocrine or neural stimuli, by assessing key parameters of human HF growth and pigmentation. Since alterations of human hair are reported in association with thyroid disease, clinically relevant parameters of human hair growth and pigmentation were assessed with top priority. Specifically, the following questions were addressed:

1. Do TH alter any of the key parameters of human HF growth and/or pigmentation (i.e. hair shaft elongation, anagen duration, follicular melanogenesis)? In particular, do THs affect the entry of human anagen VI hair follicles into catagen (Fig. 1.5)?

2. Do TH influence the proliferation or apoptosis of human hair matrix keratinocytes in situ?

3. Do TH affect the intrafollicular expression of the key catagen-inducing growth factor, TGFβ2?

4. Are there any differences between T3 and T4 in terms of their modulation of human hair growth and/or pigmentation in organ culture?

5. Do human HFs express deiodinases?

6. Do TH alter the expression of selected cytokeratins in the HF?

7. Since human HFs are an important extrarenal source and a non-classical, non-hematopoietic target of EPO, and since T3 augments EPO expression in a hepatic epithelial cell line: Does T3 up-regulate the HF expression of EPO?

8. Since TH are key regulators of metabolism: Are there any indications that TH might alter human HF mitochondrial metabolism?

1.6 Experimental Design

To address these specific questions, the following experimental design was chosen:
Scalp skin samples were collected from 7 euthyroid female donors undergoing routine face-lift surgery, and anagen VI hair follicles were micro dissected and
organ-cultured under serum-free conditions, in the presence of insulin and hydrocortisone as the only administered exogenous hormones, i.e. under severely “hypothyroid” conditions (Foitzik et al. 2006, Telek et al. 2007, Kloepper et al., 2009). Under these organ culture conditions, even amputated lower HFs, in the absence of bulge HF epithelial stem cells, continue to produce new, pigmented hair shafts at almost the speed of hair shaft production within human scalp in vivo for up to 9 days; between day 4 and 9, anagen VI then spontaneously enter into early stages of catagen transformation, until they finally begin to degenerate (Philpott et al. 1996, Kloepper et al. 2009).

During HF organ culture, the effects of selected doses of T3 or T4, which corresponded to the effective T3- concentration with which Billoni et al. (2000) had reported increased “HF survival” as well as physiologic, supra- and infraphysiologic concentration of both TH (Eisenberg et al. 2008), on hair shaft elongation were continuously recorded. At the end of experimentation, the following additional hair biology parameters were assessed by quantitative histochemistry or immunohistochemistry:

- **Hair cycle status** (histological assessment, whether the HFs were still in anagen VI or had entered into catagen)
- **HF pigmentation** (measurement of melanin content by Masson-Fontana histochemistry)
- Hair matrix keratinocyte proliferation and apoptosis in situ (measured by Ki67/TUNEL double-immunofluorescence)
- HF protein immunoreactivity for TGFβ2, EPO, cytochrome-C-oxidase (COX1), and selected keratins (CK6, CK14) in situ (measured by immunofluorescence)
- HF transcription of deiodinases that transform T4 into T3 (RT-PCR for D2 and D3)

Where appropriate, qualitative histological assessments were complemented by quantitative histomorphometry or immunohistomorphometry, and the sensitivity of routine immunohistology was enhanced by employing the highly sensitive tyramide signal amplification (TSA) or EnVision method (details, see below).
2 Materials and methods

2.1 Hair follicle isolation and organ culture

2.1.1 Hair follicle sources

The hair follicles used were isolated from skin samples derived from elective plastic surgery (face-lift). These samples have been located mostly at the occipital scalp but also at the fronto-temporal scalp of female patients with an age between 40 and 69 years. All samples were obtained from collaborating plastic surgeons after informed consent, following Helsinki guidelines, and after approval by the institutional Ethics Board of the Medical Faculty of the University of Lübeck (No. 06-109). Since there are intriguing gender-dependent differences in the HF-responsiveness to hormones, e.g. androgens and estrogens (Conrad et al. 2005, Paus et al. 2007, Ohnemus et al. 2006, Langan et al. 2009), it is important to note that all skin samples were standardized according to gender.

To assure that the samples used originated from euthyroid individuals, donor serum was collected before the surgical intervention and later examined for the thyroid status (see Table 2.1). Serum samples were kept at -20°C until further processing. Free T3, free T4, basal TSH and TG levels were assessed at the Endocrinological Laboratory, Dept. of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. Only skin samples of euthyroid donors were used except for the first patient, of whom no serum samples could be obtained, together with the skin samples. One patient with slightly elevated TG, but normal TSH level was also enrolled (Pat. 3). The skin samples were provided from patients undergoing elective face-lift surgery for cosmetic reasons in Bavaria (Dr. Dr. W. Funk, Klinik Dr. Koslowski, Munich, Germany). The scalp skin samples were kept in supplemented William’s E medium (Biochrom, Cambridge, UK) at +4°C right after being taken in the operating theatre. However, the time from ischemia until the skin was submerged in William’s E medium could not be influenced and controlled. The samples were kept tempered at +4°C and sent directly under sterile conditions in Williams´ E medium to Luebeck by overnight courier for processing within 24h after surgery.
Although a relatively stable temperature during transport can be assumed, minor quality of the samples was excluded by evaluating each sample when arriving. The evaluation included judgement of the medium colour, which can be seen as a reliable quality indicator. A light-red coloured Williams E medium indicates freshness and good tissue conservation while a deep-pink colour can be considered as outdated or unsound. The visual state of the skin sample provided the second quality marker. The samples were observed for disintegration and discolouration as signs for decay. The third quality marker was insufficient hair shaft elongation during the incubation period (HF s that failed to engage in the production of new hair shaft were eliminated from the assays). Only HFs that met these quality-control criteria were included in the subsequent analyses.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age</th>
<th>TSH (mIU/ml)</th>
<th>fT3 (pmol/l)</th>
<th>fT4 in (pmol/l)</th>
<th>TG (µg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>62</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>Not assessed</td>
</tr>
<tr>
<td>2</td>
<td>50</td>
<td>1.60</td>
<td>7.84</td>
<td>14.09</td>
<td>Not assessed</td>
</tr>
<tr>
<td>3</td>
<td>40</td>
<td>0.448</td>
<td>4.46</td>
<td>12.15</td>
<td>93.55</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
<td>2.89</td>
<td>6.99</td>
<td>17.51</td>
<td>7.84</td>
</tr>
<tr>
<td>5</td>
<td>51</td>
<td>2.46</td>
<td>7.22</td>
<td>17.94</td>
<td>3.08</td>
</tr>
<tr>
<td>6</td>
<td>49</td>
<td>1.81</td>
<td>6.46</td>
<td>18.89</td>
<td>7.59</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>0.761</td>
<td>4.04</td>
<td>17.08</td>
<td>6.80</td>
</tr>
</tbody>
</table>

Reference value*  

Table 2.1 Thyroid status of all patients, whose HFs were examined

*Reference values according to the endocrine laboratory, medical clinic I, university of Luebeck, Luebeck, Germany

2.1.2 Micro dissection of human anagen VI hair follicles

HF isolation under sterile conditions followed the standard HF organ culture assay introduced by Philpott et al. (1990), with minor modifications (see below), employing a greatly extended set of experimental read-out parameters an (Bodó et al. 2007a, Foitzik et al. 2006, Ito et al. 2005, Kloepfer et al., 2009). During the process of HF isolation, skin samples were kept in Williams’ E medium. Per 100ml William’s E 1ml antimycotic/ antibiotic mixture containing 10,000 units of penicillin
(base), 10,000 µg of streptomycin (base), and 25 µg of amphotericin B per ml (Invitrogen, Carlsbad, California) was added.

Skin samples were cut into rectangles of about 1cm length. Under a stereomicroscope (Carl Zeiss MicroImaging Inc., Oberkochen, Germany), epidermis and dermis were mechanically separated from the subcutis after identification of the border between the dermis and the subcutis. The cutting line was placed slightly distal to the border (towards the dermis), so that the reticular structure of the connection between the dermis and the subcutis became clearly visible. With a little pressure on the outer edges of the piece of the sample, macroscopically clearly visible pigmented anagen hair bulbs were then elevated above the subcutis-level and gently plucked out with forceps. Since this is crucial for later HF organ culture and HF vitality, the ORS and CTS of plucked HFs had to stay intact during the whole procedure.

For organ culture, micro dissected and amputated proximal HFs were transferred to fresh culture medium: Williams' E medium (Biochrom, Cambridge, UK), supplemented with 2mmol/L L-glutamine (Invitrogen, Carlsbad, California), 10µg/ml insulin (Sigma-Aldrich, Taufkirchen, Germany), 10ng/ml hydrocortisone (Sigma-Aldrich, Taufkirchen, Germany), and 1ml penicillin/streptomycin mixture (10,000 units of penicillin (base) and 10,000 µg of streptomycin (base)/ml; Invitrogen, Carlsbad, California).

Figure 2.1 Hair follicles in culture well plate and scheme magnification 20x
For this analysis only pigmented, intact terminal anagen VI hair follicles were used, which were clearly identified under low magnification by morphological criteria, namely the presence of a fully pigmented, characteristically shaped anagen hair bulb (Kloepper et al. 2009) (see Fig. 2.1). These HF s were randomly allocated to 24- multiwell plates (Greiner Bio One, Wemmel, Belgium): 3 hair follicles were cultured in one well (Fig. 2.1), and each well was filled with 500 µl of culture medium. HFs were incubated at 37°C, 95% O₂, 5% CO₂ in a Hera cell incubator (Heraeus, Kendro, Artisan Scientific Corporation, Champaign, IL, United states) for either 5 or 9 days.

2.1.3 T3 and T4-treatment in hair follicle organ culture
The plucked hair follicles were divided into 7 groups to test 3 different concentrations of each thyroid hormone compared to one group as a control. Each group consisted of 18 follicles, which resulted in 6 wells per group on a 24-multiwell plate (only 3 HF were incubated per well). The procedure was repeated 7 times using skin samples of 7 different female patients.

All groups were kept for 24 hours in the culture medium prior to the start of experimentation in order to minimize the effects of stress caused by the micro dissection and plucking process by providing this equilibration period. 1mg of T3 or T4 were dissolved in 1.0 normal natriumhydroxide diluted in culture medium in the concentrations listed below and were added for the first time after the 24 hours equilibration period, and then every second day, during alternating day medium changes. Triiodothyronine (T3) and L- thyroxine (T4) (both: Sigma-Aldrich, Taufkirchen, Germany) were tested at different concentrations and in cultures lasting 5 or 9 as outlined in table 2.2.

We used T3-concentrations of 10⁻¹², 10⁻¹⁰ and 10⁻⁸ mol L⁻¹ covering the effective concentration with which Billoni et al. (2000) had reported increased “HF survival”. For T4 ,a physiologic concentration of 10⁻⁷ mol L⁻¹ was applied, as well as infra- (10⁻⁸ mol L⁻¹) and supra- (10⁻⁶ mol L⁻¹) physiologic concentrations. As normal ranges of thyroid hormone serum levels for T4 are 5-12 microg/dL (= 6.4 x 10⁻⁸ mol L⁻¹ - 1.5 x 10⁻⁷ mol L⁻¹) and for T3 are 0.8-1.9 ng/mL(= 1.2 x 10⁻⁹ mol L⁻¹ - 2.9 x 10⁻⁹ mol L⁻¹) (Eisenberg et al. 2008).
<table>
<thead>
<tr>
<th></th>
<th>day 1</th>
<th>day 3</th>
<th>day 5</th>
<th>day 7</th>
<th>day 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>Add culture medium (CM)</td>
<td>Medium change</td>
<td>Medium change or freeze</td>
<td>Medium change</td>
<td>freeze</td>
</tr>
<tr>
<td>T3 1pM</td>
<td>Add CM with T3 [1pM]</td>
<td>Medium change</td>
<td>Medium change or freeze</td>
<td>Medium change</td>
<td>freeze</td>
</tr>
<tr>
<td>T3 100pM</td>
<td>Add CM with T3 [100pM]</td>
<td>Medium change</td>
<td>Medium change or freeze</td>
<td>Medium change</td>
<td>freeze</td>
</tr>
<tr>
<td>T3 10nM</td>
<td>Add CM with T3 [10nM]</td>
<td>Medium change</td>
<td>Medium change or freeze</td>
<td>Medium change</td>
<td>freeze</td>
</tr>
<tr>
<td>T4 10nM</td>
<td>Add CM with T4 [10nM]</td>
<td>Medium change</td>
<td>Medium change or freeze</td>
<td>Medium change</td>
<td>freeze</td>
</tr>
<tr>
<td>T4 100nM</td>
<td>Add CM with T4 [100nM]</td>
<td>Medium change</td>
<td>Medium change or freeze</td>
<td>Medium change</td>
<td>freeze</td>
</tr>
<tr>
<td>T4 1µM</td>
<td>Add CM with T4 [1µM]</td>
<td>Medium change</td>
<td>Medium change or freeze</td>
<td>Medium change</td>
<td>freeze</td>
</tr>
</tbody>
</table>

**Table** Fejl! Brug fanen Startside til at anvende Abbildungsverzeichnis;Figures på teksten, der skal vises her. Fejl! Brug fanen Startside til at anvende Abbildungsverzeichnis;Figures på teksten, der skal vises her. **2.2 Scheme of HF treatment in organ culture**

At days 5 or 9, groups of 3 HFs cultured together in of one well were removed from the culture medium and placed onto a metal plate for freezing. They were covered with Shandon- Tissue Cryomatrix (Frozen Embedding Compound, Thermo Fisher Scientific Inc., Waltham, MA, United States) and carefully deep-frozen using fluid nitrogen. The hair follicles embedded in Shandon- Tissue were afterwards released from the plate and kept in plastic tubes at -80°C until further processing. For this study, longitudinal frozen sections of 7 µm thickness were produced with a Leica CM 3500 cryostat and devolved on superfrost plus (Menzel GmbH & Co KG, Braunschweig, Germany) slides. To obtain evaluable sections, 5 longitudinal sections through the dermal papilla and the hair shaft were performed on each block of deep frozen hair follicles. Cryoslides were stored at – 80°C until further use.
HF culture and snap-freezing were conducted under highly sterile conditions. Cryosectioning times were kept as short as possible to diminish the period samples were not kept at -80°C, but -21°C.

2.1.4 Measurement of hair shaft elongation

The length of every individual hair follicle was measured using a Zeiss inverted binocular microscope with an eyepiece measuring graticule (Zeiss Stemi 2000-C, Carl Zeiss MicroImaging Inc., Oberkochen, Germany). Therefore, the HF's were paralleled with a measuring scale and their length was assessed from the tip of the DP stalk up to the end of the hair shaft (see Fig. 2.1). Since the eyepiece measuring graticule only provides a virtual unit, the assessed value was expressed as percent of the original HF length. This allows one to compare the hair shaft elongation between groups, donors, and individual HF's. Hair shaft
elongation was measured as described at day 0, 1, 3, 5 (5 day protocol) and at day 0, 1, 3, 5, 7, 9 (9 day protocol).

2.2 Quantitative hair cycle and hair pigmentation histomorphometry

Staging of the hair follicle cycling was carried out according to previously defined, exact morphological criteria (Müller-Rover et al. 2001 Stenn and Paus 2001, Sheehan et al. 2004), using a refined set of objective criteria that was specifically developed for the current thesis project (Kloepper et al. 2009) to determine the percentage of follicles in anagen and early, mid or late catagen. Human anagen hair follicles in vitro normally do not enter into the telogen phase in organ culture, because they degenerate before having reached this stage of HF transformation (Philpott et al. 1994). Table 2.3 shows the criteria according to which the HFs were staged, and Figure 2.3 illustrates these criteria.

<table>
<thead>
<tr>
<th></th>
<th>anagen</th>
<th>early catagen</th>
<th>mid catagen</th>
<th>late catagen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermal papilla</td>
<td>onion- shaped</td>
<td>onion- shaped</td>
<td>ball- shaped</td>
<td>ball- shaped</td>
</tr>
<tr>
<td>Matrix keratinocytes</td>
<td>nearly surrounding DP</td>
<td>proximal opening</td>
<td>surrounding less than 50% of the DP</td>
<td>touching DP with epithelial stroma</td>
</tr>
<tr>
<td>DP-fibroblasts</td>
<td>vertical order</td>
<td>jumbled</td>
<td>dense</td>
<td>Dense</td>
</tr>
<tr>
<td>melanocytes</td>
<td>many dendrites</td>
<td>no dendrites</td>
<td>no dendrites, diminished</td>
<td>no dendrites, diminished</td>
</tr>
<tr>
<td>morphology</td>
<td>A</td>
<td>B</td>
<td>C</td>
<td>D</td>
</tr>
</tbody>
</table>

Table 2.3 Criteria for classification of HF in anagen and different stages of catagen

Figure 2.3 HF in different stages (see Kloepper et al. 2009)
A) anagen HF, B) early catagen HF, C) mid catagen HF, D) late catagen
DP = dermal papilla, MK = matrix keratinocytes, → = indicating melanocytes

The Masson-Fontana histochemistry was used for studying both, hair follicle morphology and for visualizing melanin pigment (Barbosa et al. 1984). The argentaffin melanin is detectable via silver uptake and reduction to its visible metallic state without any reducing agent needed. 7 µm thick cryosections of cultured HFs were air-dried, fixed in ethanol-acetic acid (2:1) and after washing with TBS buffer and distilled water processed with silver nitrate (Merck & Co., Inc., NJ, USA) 10% for 40 minutes. Silver nitrate powder was dissolved in distilled water, 40% NaOH was added droplet-wise until black/brown precipitate could be seen in the solution. Afterwards the precipitate was soluted by adding ammonium hydroxide. Sodiumthiosulfate (Merck & Co., Inc., NJ, USA) 5% fixed the silver nitrate during 1 minute and counterstaining with Mayer’s haematoxylin (Chroma, Muenster, Germany) was performed. The staining was concluded by dehydration of the slides in ethanol of ascending concentrations and finally a xylol-substitute solution (Vogel, Karlsruhe, Germany). Since the human HF has a clearly defined pigmentary unit (see above) and non-pigmented CTS, we used the untreated HF itself as positive and negative control.

2.3 Immunohistochemistry

For all assessments with immunohistochemistry as positive controls published follicular IR-patterns were reproduced along with every staining carried out as well as negative controls by omitting primary antibody. Only results that were reproducible in at least 3 different patients (yielding to 54 hair follicles per group) were considered and are reported.

To evaluate apoptotic cells in co-localization with a proliferation marker Ki67, a Ki67/TUNEL (terminal dUTP nick-end labelling) double-staining method was used (Bodó et al. 2007a). Cryosections were fixed in paraformaldehyde and ethanol-acetic acid (2:1). After incubation with equilibration buffer for 5 minutes the sections were labelled with a digoxigenin-deoxyUTP (ApopTag Fluorescein, In Situ Apoptosis detection kit; Intergen, Purchase, NY) in the presence of terminal
deoxynucleotidyl transferase (TdT) for 60 minutes at 37°C (ApopTag Fluorescein, In Situ Apoptosis detection kit; Intergen, Purchase, NY) mixed with reaction buffer (3:7). The reaction was stopped by stopping buffer at 37 °C for 10 minutes and was followed by pre-incubation with goat serum 10% and then mouse anti-Ki67 antiserum (1:20 in PBS, over night at 4 °C; DAKO, Glostrup, Denmark).

<table>
<thead>
<tr>
<th>Primary antibody</th>
<th>origin</th>
<th>dilution</th>
<th>Reference tissue (positive control)</th>
<th>Literature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Ki67</td>
<td>mouse</td>
<td>1:20</td>
<td>murine spleen</td>
<td>(Libiani et al. 2008)</td>
</tr>
<tr>
<td>TdT</td>
<td></td>
<td>3:7</td>
<td>4-HC-treated skin</td>
<td>(Bodó et al. 2007b)</td>
</tr>
<tr>
<td>Anti-TGF-β2</td>
<td>rabbit</td>
<td>1:50</td>
<td>Human placenta</td>
<td>(Tarrade et al. 2001)</td>
</tr>
<tr>
<td>Anti-COX1</td>
<td>mouse</td>
<td>1:40</td>
<td>Human skin</td>
<td>(Li et al. 2007, Bodó et al. 2009b)</td>
</tr>
<tr>
<td>Anti-Epo</td>
<td>rabbit</td>
<td>1:50</td>
<td>Human kidney</td>
<td>(Bodó et al. 2007a)</td>
</tr>
<tr>
<td>Anti-CK14</td>
<td>mouse</td>
<td>1:200</td>
<td>Human skin</td>
<td>(Olszewska and Sudhoff 2007)</td>
</tr>
<tr>
<td>Anti-CK6</td>
<td>mouse</td>
<td>1:10</td>
<td>Human skin</td>
<td>(Demirkesen et al. 1995)</td>
</tr>
</tbody>
</table>

Table 2.4 Primary antibodies used and reference tissues employed as positive controls

### 2.3.1 Ki67/TUNEL

TUNEL-positive cells were visualized by an anti-digoxigenin FITC-conjugated antibody (ApopTag kit) diluted in blocking solution (56 locking solution : 59 antibody), whereas Ki67 was detected by a rhodamine-labeled goat anti-mouse antibody (Jackson ImmunoResearch, West Grove, PA) 1:200 in PBS with 2% goat normal serum (DAKO, Glostrup, Denmark). Counterstaining was performed with DAPI (Boehringer Mannheim GmbH, Mannheim, Germany) for 1 minute. For all washing steps PBS buffer was used.

Negative controls were performed by omitting TdT and the Ki67 antibody as well as by demonstrating the absence of specific Ki67 or TUNEL immunoreactivity in those cell populations that are expected from the literature to be negative for these markers (Kloepper et al. 2009). Proliferating matrix/epidermal keratinocytes of normal human skin and frozen sections of human spleen were used as additional positive control tissues for Ki67 expression, while sections of HF5s that had been treated with 4-hydroperoxycyclophosphamide -, which strongly up-regulates the
number of TUNEL+ cells in the hair matrix (Bodó et al. 2007b), were used as were used as additional positive control for the TUNEL reaction.

Quantitative immunohistomorphometry was performed in carefully defined, microscopically assessed reference areas as described previously (Foitzik et al. 2006, Bodó et al. 2007a+b): Ki67-, TUNEL-, or DAPI-positive cells were counted in a reference region of the HF matrix defined as all matrix keratinocytes below a line parallel to Auber’s line touching the most distal tip of the DP. The percentage of Ki67- positive and TUNEL-positive cells was determined proximal of this line (Fig.2.4). This reference region was chosen instead of the usual region proximal of the Auber’s line, because proliferational and apoptotic changes also seemed to affect the matrix keratinocytes distal of the Auber’s line (Kloepper et al. 2009).

2.3.2 TGFβ2

To investigate transforming growth factor- β2 (TGFβ2) expression, cryosections were acetone-fixed whereupon endogenous peroxidases were blocked with 3% H₂O₂ (Merck & Co., Inc., NJ, USA) for 15 minutes followed by treatment with avidin and biotin (Vector laboratories, Burlingame, CA, USA), each for 15 minutes. After a pre-incubation of 30 minutes with 5% goat normal serum (DAKO, Glostrup, Denmark) in TNT buffer, the slides were incubated first with the primary antibody for TGF- β2 (rabbit anti-human, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) 1:50 in TNT with 2% goat normal serum (DAKO, Glostrup, Denmark), over night at +4 °C. At the second day, the slides were incubated first with biotinylated goat anti-rabbit (Jackson ImmunoResearch) secondary antibodies 1:200 in TNT with 2% goat normal serum (DAKO, Glostrup, Denmark), for 45 min, RT, and then with Streptavidin-conjugated horseradish peroxidise (HRP, 1:100 in TNT) provided
in the TSA kit (Perkin-Elmer, Boston, USA) for another 30 minutes. To complete the amplification, all slides were treated with FITC-tyramide amplification reagent 1:50 in amplification diluent (TSA kit; Perkin-Elmer, Boston, USA) at room temperature. Counterstaining was performed with DAPI (Boehringer Mannheim, Mannheim, Germany) for 1 minute. Negative controls were performed by omitting the primary antibody. For all washing steps TNT buffer was used. As positive control human placenta tissue was used (Tarrade et al. 2001).

2.3.3 COX1
For the detection of COX1 (cytochrome-C-oxidase, Complex IV subunit I) the peroxidase-based avidin-biotin complex method (Vector laboratories, Burlingame, CA, USA) was used, as described (Foitzik et al. 2006, Bodó et al. 2009b). After fixation in acetone at -20°C, quenching of endogenous peroxidases with 3% H₂O₂ (Merck & Co., Inc., NJ, USA), and blocking of non-specific binding sites by pre-incubation with goat normal serum (10% in TBS, DAKO, Glostrup, Denmark) for 20 minutes at RT, cryosections were incubated with monoclonal mouse anti-human Complex IV subunit I antibody (Clone MS404, Mitosciences, Eugene, OR, USA) at a dilution of 1:50 in TBS with 2% goat normal serum (DAKO, Glostrup, Denmark) over night at +4°C.

As secondary antibody, biotinylated goat anti-mouse IgG (PNIM 0816, Beckmann Coulter, Marseille, France) 1:200 in TBS with 2% goat normal serum (DAKO, Glostrup, Denmark) was administered for 45 minutes at RT and then the slides were treated with an avidin-biotin kit peroxidase (Vector laboratories, Burlingame, CA, USA) for 30 minutes followed by AEC substrate- chromogen system (DAKO, Glostrup, Denmark) for 8 minutes. The primary antibodies were replaced by buffer for negative controls. Human skin served as positive control tissue, since it expresses high amounts of COX1 protein in epidermal keratinocytes (Li et al. 2007). Counterstaining was performed with Mayer’s hemalaun (Chroma, Muenster, Germany) for 5 minutes. For all washing steps TBS buffer was used.
2.3.4 EPO

Immunostaining for EPO in vehicle/T3/T4-treated follicles was performed using the highly sensitive EnVision® (Dako, Glostrup, Danmark) technique as described before (Bodó et al. 2007a). Acetone-fixed cryosections were, after pre-incubation with goat normal serum (10% in TBS) for 20 minutes, incubated with a rabbit anti-human EPO antiserum (generated by hyper-immunization of rabbits with recombinant human EPO; kindly provided by A. Kromminga, Institute for Immunology, Clinical Pathology, Molecular Medicine, Hamburg, Germany) at a dilution of 1:50 in TBS over night at 4°C. Washing steps were performed with TBS buffer. Slides were then treated with the EnVision labelled polymeric secondary antibody solution (Dako, Glostrup, Denmark) goat anti rabbit/mouse immunoglobulin for 30 minutes at RT, followed by staining with fast red tablets (Sigma-Aldrich, Taufkirchen, Germany) for 5 minutes. Counterstaining was performed with Mayer’s haematoxylin (Chroma, Muenster, Germany) for 1 minute. Negative control experiments were performed by omitting primary antibody, while human kidney sections served as positive control tissue, since kidney epithelium is the key source of EPO production (Jelkmann 2004). 

2.3.5 CK14

For the detection of cytokeratin 14 (CK 14) the peroxidase-based avidin-biotin complex method (Vector laboratories, Burlingame, CA, USA) was used. After fixation in acetone at -20°C and blocking of endogenous peroxidases with 3% H₂O₂ cryosections were pre-incubated with goat normal serum (Dako, Glostrup, Denmark) 10% in TBS and incubated with monoclonal mouse anti-human CK 14 antibody (Sigma-Aldrich, Taufkirchen, Germany) 1:200 in TBS with 2% goat normal serum (DAKO, Glostrup, Denmark) over night at 4°C. The staining was performed with biotinylated goat anti-mouse IgG (Beckmann Coulter, Marseille, France) as secondary antibody 1:200 in TBS with 2% goat normal serum (DAKO, Glostrup, Denmark) for 45 min at RT. Washing steps were performed with TBS buffer. Then an avidin-biotin peroxidase kit (Vector laboratories, Burlingame, CA, USA) for 30 minutes followed by AEC substrate-chromogen system (Dako, Glostrup, Denmark) for 5 minutes, both at RT, served as staining substrate.
As negative controls, the primary antibodies were omitted. Human skin (epidermis) was used as a positive control for CK14, since the basal and suprabasal layer of human epidermis is strongly positive for CK14 (Olszewska and Sudhoff 2007). Counterstaining was performed with Mayer’s haematoxylin for 1 minute.

2.3.6 CK6

To investigate the expression of human keratin 6 (CK6) (Langbein and Schweizer 2005), acetone-fixed cryosections were pre-treated with non-immune goat serum (Dako, Glostrup, Danmark) 10% in TBS. Cryoslides were first incubated with the primary antibodies against CK6 (mouse anti-human, PROGEN, Heidelberg, Germany) 1:10 in TBS with 2% non-immune goat serum (DAKO, Glostrup, Denmark) over night at 4°C, then with rhodamine-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA, USA) 1:200 in TBS with 2% non-immune goat serum (DAKO, Glostrup, Denmark) for 45 minutes at RT. Counterstaining was performed with DAPI (Boehringer Mannheim, Mannheim, Germany) for 1 minute.

Human scalp skin was used as a positive control, since the ORS of human HF strongly expresses CK6 (Demirkesen et al. 1995, Havlickova et al. 2009), while the negativity of CK6-like immunoreactivity in the central hair matrix and the epidermis as well as HF sections without application of primary antibody served as adequate negative controls. Washing steps were performed using TBS buffer.

2.4 Quantitative immunohistomorphometry

For quantitative immunohistochemistry of carefully defined reference areas, densitometric measurement of the intensity of immunoreactivity was performed using the ImageJ/NIH-image software (National Institute of Health, Bethesda, USA), as previously described (Ito et al. 2005, Foitzik et al. 2006, Bodó et al. 2007a). For light microscopic immunohistochemistry and immunofluorescence, pictures were analysed in RGB colour. Measurements were performed in the ORS at a distance of three microscopic fields in a 200x magnification, distal to the dermal papilla. Only for the assessment of TGF-β2 immunoreactivity, a distance of one microscopic field from the DP was chosen. For each HF, two
measurements were performed, one on each side of the hair shaft, and a mean value was calculated. Densitometric measurement of melanin staining intensity was also performed with ImageJ/ NIH-image software (National Institute of Health, Bethesda, USA) using 8bits black and white pictures. Previously defined reference areas of interest in the hair matrix (Ito et al. 2005) were used to calculate the average values.

![Reference areas for evaluation of the different stainings](image)

**Figure 2.5** reference areas for evaluation of the different stainings

= reference area for densitometric measurement, = reference area for TGFβ2 TSA staining, = reference area for CK6, CK14, COX1 and EPO; MK = matrix keratinocytes, DP = dermal papilla, HS = hair shaft, ORS = outer root sheath, IRS = inner root sheath

### 2.5 RT-PCR: Deiodinases

**Semi quantitative reverse transcriptase (RT)-PCR for D2 and D3 deiodinases**

For the semi quantitative PCR analysis of expression of D2 (gene bank accession no. AF093774) and D3 (accession no. NM 001362) total RNA was isolated from micro dissected HFs using the RNA easy kit (Qiagen, Hilden, Germany). 0.5 µg of total RNA was reverse-transcribed with SuperScript First-Strand Synthesis System (Applied Biosystems, Foster City, CA, USA). The quality and quantity of cDNA in all samples were standardized by the amplification of housekeeping gene GAPDH as described previously (Zmijewski et al. 2007).

The PCR conditions for D2 and D3 amplification were as follows: initial denaturation 95 °C for 2 minutes followed by 30 cycles of: denaturation at 94 °C for 30 seconds; annealing at 60 °C for 30 seconds, elongation 72 °C for 30 seconds.
The final elongation step was at 72°C for 5 minutes. The primers used for amplification were described previously (Slominski et al., 2002) and purchased from Integrated DNA Technology Inc., (Corallville, IA, USA).

For detection of D2, PCR reaction was repeated with a second pair of primers and 0.5 µl of reaction mixture from the first round. PCR products were visualized on 2% agarose gel with ethidium bromide. Data of D2 and D3 expression were normalized to the expression of GAPDH of the same sample. Non-template control (by omitting RNA) and samples not containing reverse transcriptase were used as negative controls, while control RNA from the RNA easy kit served as another positive control.

2.6 Statistical analysis

Statistical analysis was performed using the Mann Whitney U Test for unpaired samples. The p-values were calculated using the statistical analysis software SPSS (SPSS Inc., Chicago, USA). p values of *< 0.5; **≤ 0.01; ***≤ 0.001 were regarded as significantly different. To evaluate immunohistochemical data, per staining reaction and evaluated reference area, each concentration of T3 and T4 was compared to the vehicle employing the Mann Whitney U Test. The testing was performed per patient and then cumulated. Resulting significant and non-significant outcomes are reported here.

For every parameter examined, 18 HF were cultured per TH- concentration and compared to 18 vehicle-treated control- HF. This procedure was performed with the HF of three different female donors. The resulting data from all three patients were pooled, since HF responses to TH stimulation turned out to congruent between all three patients. This gave a total n of 54 HFs per TH-concentration/control per test/control group.
3 Results

3.1 T4 stimulates human hair matrix keratinocyte proliferation, while both T3 and T4 inhibit apoptosis of these cells

First, we investigated proliferation and apoptosis of matrix keratinocytes by Ki67/TUNEL double-staining and quantitative immunohistomorphometry after T3 and T4-treatment. Whether T3 (1 pM, 100 pM, 10 nM) and/or T4 (10nM, 100nM, 1000 nM) modulate human hair matrix keratinocyte proliferation and apoptosis when added directly to the serum-free medium of micro dissected, organ-cultured normal human scalp HFs was analysed on HFs that were in the stage of maximal growth during HF cycling (anagen VI).

![Figure 3.1](image-url) T4 stimulates human hair matrix keratinocyte proliferation and both T3 and T4 inhibit hair matrix keratinocyte apoptosis

percentage of positive cells was compared between vehicle and T3/ T4 treated follicles. *$P \leq 0.05$, **$P \leq 0.01$, significances compared to control; examined on 5 days culture; mean ± SEM.

As shown in Fig. 3.1 and Fig. 3.2, the proliferation of hair matrix keratinocytes was significantly stimulated by T4 seen in the increased amount of Ki67- positive cells,
while the proliferation-modulatory effects of the T3 concentrations tested did not reach the level of significance. However, both T3 and T4 significantly reduced the number of TUNEL-positive matrix keratinocytes displaying a reduced apoptosis in defined reference areas (Fig. 3.1 and 3.2). Thus, both TH exerted slightly differential, but complementary growth-promoting effects on the most rapidly proliferating epithelial cell population of mammalian skin in situ.

**Figure 3.2 Apoptosis and proliferation of TH-treated HFs**

Cryosections of cultured HFs treated with vehicle, T3 or T4 were double-immunoabelled for Ki-67 (red) and TUNEL (green). After 5 days of culturing; Ki67 and TUNEL positive cells were counted below a line marking the tip of the dermal papilla (indicated in red). DP = Dermal papilla, MK = Matrix keratinocytes.
3.2 T3 and T4 do not significantly alter human hair shaft structure formation in vitro

However, during the relatively short HF organ culture period (9 days), these effects on the hair matrix keratinocyte proliferation/apoptosis did not result in marked, histological detectable alterations of the actual hair shaft morphology (Fig. 3.3 C1-C3), and no abnormalities in hair shaft pigmentation became apparent. Also, hair shaft production over 9 days of serum-free organ culture was not significantly modified by the tested doses of T3 and T4. When measuring the rate of hair shaft elongation in vitro, this remained essentially unaltered by THs, compared to vehicle controls, even though two of the tested T3 doses showed a tendency towards slightly enhanced hair shaft formation in vitro, compared to vehicle controls. However, no significant, reproducible stimulatory effects on hair shaft production were detected either after T3 or after T4 treatment (Fig. 3.3 A+B) could not be detected (p>0.05).
Figure 3.3 Hair shaft elongation and morphology
A) percent of hair shaft elongation measured every second day and compared to day 0, B) percentage of hair shaft elongation after 9 days of HF organ culture, mean ± SEM; all tested concentrations (T3/ T4) not significantly different from the control group (p>0.05)., C) hair shaft morphology, C1) control, C2) T3 1pM, C3) T4 1000nM, scale bars = 50 µm; ORS = outer root sheath, IRS = inner root sheath, HS = hair shaft.
3.3 Both T3 and T4 prolong anagen duration

Clinically, the most important effect that any hair loss-inhibitory or hair growth-promoting agent can have is to prolong the duration of anagen, which is indistinguishable from an inhibition of catagen development. Therefore, we tested by quantitative hair cycle histomorphometry whether TH-treated human HFs showed any evidence of such an effect. Masson-Fontana stained HF sections were employed to assess the hair cycle status, using a set of newly defined, objective criteria that were specifically developed for this thesis project (Kloepper et al. 2009).

Both T3 and T4 increased the percentage of anagen HFs, and decreased the percentage of catagen HFs after 5 (Fig. 3.4 A) or 9 days in organ culture (Fig. 3.4 B). This provides the first objective evidence that THs are potent modulators of human scalp HF cycling, at least in vitro.
Comparing the hair cycle effects of T3 and T4 over vehicle controls after 5 and 9 days of organ culture did not reveal major differences between both THs. At both end-points, the relative distribution of anagen and catagen HFs displayed a similar pattern. Due to the very limited total number of available human scalp HFs that could be studied, the number of different T3 and T4 doses tested was insufficient to allow any solid conclusions on dose-dependency of the observed hair cycle effects. Nevertheless, the anagen-prolongation by T3 appeared to be in line with a dose-dependent effect. No such trend was seen with T4.
3.4 TGFβ2 immunoreactivity is down-regulated by thyroid hormones

Since, under physiological conditions, TGFβ2 appears to be the most important endogenous stimulus for catagen induction in human scalp hair follicles (Hibino and Nishiyama, 2004, Foitzik et al. 2005, Paus and Foitzik 2004), the hair cycle data generated above were complemented with quantitative immunohistomorphometric assessment of the effect of THs on TGFβ2 immunoreactivity in human HF organ culture. Specifically, we tested whether the anagen prolongation by TH was associated with an altered intrafollicular expression of TGF-β2.

Although substantial inter-individual variations in intrafollicular TGFβ2 IR intensity and patterns were noted between the HFs derived from different patients (data not shown), quantitative immunohistomorphometry revealed that TH treatment results in a discrete, but significant reduction of TGFβ2 IR in the proximal hair bulb epithelium (p<0.05) (Fig 3.5 A-C).
Figure 3.5 Histomorphometry of TGF-β2 immunoreactivity (IR)

A) quantification of TGFβ2 IR in arbitrary units, using equivalent fields of the distal ORS, p values compared to control, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, mean in percent ± SEM. B) control C) T4; TGFβ2 was evaluated on 9 days culture, ORS = outer root sheath, CTS = connective tissue sheath, DP = dermal papilla, dotted line to facilitate overview (the area between the dotted lines represents the CTS).

This independently confirms a catagen-inhibitory effect of THs, and is in line with the concept that a (direct or indirect) inhibition of the intrafollicular production of TGFβ2, a key catagen-promoting growth factor, may explain at least in part the catagen-inhibitory activity of both T3 and T4.
3.5 T3 and T4 differentially modulate follicular keratin expression

Next, we assessed TH actions on the intra-follicular protein expression for two cytokeratins with recognized TH-responsive elements (TRE), namely human cytokeratin 14 and cytokeratin 6 (Radoja et al. 1997).

Interestingly, CK 6 IR was significantly increased after treatment with 1pM T3 and 10nM T4 and 1µM T4 (p< 0.05) (Fig. 3.6 A-C, H). Instead, by quantitative immunohistomorphometry, the IR for CK 14 IR was significantly decreased in all TH-treated HFs (p<0.001) (Fig. 3.6 D-F, G).
Figure 3.6  Differential effect of TH on human hair keratin protein expression in situ

A) Cytokeratin 6 protein expression detected by IF is significantly altered by both T4 and T3, quantification of CK6-IF,
B-D) Cytokeratin 6 IR in the distal ORS: B) control, C) T3 1pM, D) T4 10nM;
E) T3 and T4 down regulate Cytokeratin 14 IR significantly, quantification of CK14-IR;
F-H ) Cytokeratin 14 IR in the distal ORS: F) control, G) T3 100pM, H) T4 10nM;
cytokeratins evaluated on 5 days culture;  *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; mean ± SEM, scale bars = 50 µm; ORS = outer root sheath, IRS = inner root sheath, HS = hair shaft;  □□□□, □□□□ = areas measured
3.6 T3 and T4 stimulate hair follicle pigmentation

Next, we tested whether TH modulated intrafollicular melanin synthesis. Since follicular melanogenesis is strictly coupled to HF cycling and seizures in catagen (Slominski et al. 2005), it was critical to compare only anagen VI HFs from test and control groups with each other, carefully excluding all catagen HFs from the analysis.

As revealed by quantitative Masson-Fontana histochemistry, both T3 and T4 significantly (p<0.001, p<0.01) stimulated human HF melanin synthesis, with supra-physiological concentrations of T4 showing the strongest stimulation of HF melanogenesis (Fig. 3.7 A and B1 to D1). Focussing on the measurable effects of TH on HF pigmentation it was noteworthy that, after 5 days of organ culture, T3 showed the strongest HF melanisation-enhancing effect, T3 and T4 were equally pigmentination-enhancing after 9 days. This means that, even though anagen VI HFs already maximally engage in melanogenesis (Slominski et al. 2005), TH can further stimulate intrafollicular pigment production under organ culture conditions.
Figure 3.7  T3 and T4 stimulate the hair follicle pigmentation

A) quantification of histochemical staining intensity for melanin (Masson-Fontana histochemistry), **$P \leq 0.01$, ***$P \leq 0.001$, mean ± SEM, significances compared to control; B1+2) control, C1+2) T3 1pM, D1+2) T4 100nM; scale bars = 50 µm, magnification in B2,C2 and D2 600x; DP = Dermal papilla, MK = matrix keratinocytes; → = indicating melanocytes.

High power magnification of Masson-Fontana-stained HF sections suggested that TH treatment not only stimulated the total hair bulb melanin content, but also stimulated HF melanocyte dendricity (Fig. 3.7 B2, C2, D2). Unfortunately, the strength of the melanin-associated argentaffine histochemical signals hindered definitive confirmation of this intriguing observation.
3.7 Thyroid hormones enhance follicular erythropoietin immunoreactivity

Given the reported effect of TH on erythropoietin (EPO) expression in a liver cell line (Ma et al. 2004) and the previous discovery that human HFs are non-hematopoietic targets and extra-renal production sites for erythropoietin, we also examined whether TH can alter the EPO protein expression in human HFs.

As shown in Fig 3.8, both T3 and T4 slightly up-regulated EPO IR in the ORS of human scalp HF after 9 days of organ culture in the presence of these THs. For T3, this up-regulation reached significance at a concentration of 100pM, for T4 at 1µM. Both these concentrations correspond to supraphysiological serum levels (T4: 6.4 x 10^{-8} mol L^{-1} - 1.5 x 10^{-7} mol L^{-1} and T3: 1.2 x 10^{-9} mol L^{-1} - 2.9 x 10^{-9} mol L^{-1}; Eisenberg et al. 2008).
Figure 3.8  Thyroid hormones enhance follicular erythropoietin immunoreactivity (IR) in situ

A) quantification of EPO-IR in the ORS, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; mean ± SEM, significances compared to control, B) control, C) T3 100pM, D) T4 100nM; 9 days culture; scale bars = 50 µm; ORS = outer root sheath, IRS = inner root sheath, HS = hair shaft; = reference areas measured
3.8 Cytochrome-c-oxidase subunit 1 (COX1) immunoreactivity is up regulated by T3 and T4

Furthermore, we investigated whether TH up-regulate protein expression for a key enzyme of mitochondrial energy metabolism, Cytochrome-c-oxidase subunit 1 (COX1)

Here we show by quantitative immunohistomorphometry that T3 and T4 indeed both up-regulate the IR for the key respiratory chain enzyme COX1 in the outer root sheath of human scalp HFs.

**COX 1 - IR**
Figure 3.9  Cytochrome-c-oxidase immunoreactivity is stimulated by T3 and T4

A) quantification of COX1- IR, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; mean ± SEM, significances compared to control; B1+2) control, C1+2) T3 100pM, D1+2) T4 100nM; 9 days culture; scale bars = 50 µm; ORS = outer root sheath, IRS = inner root sheath, HS = hair shaft; [ ] = areas measured.

The IR pattern was strictly spot-like and not homogenously distributed. Since the enzyme is mitochondrial encoded and located only in the respiratory chain of mitochondria (Sheehan et al. 2004), this staining pattern reflects the distribution of COX1 as well as that of mitochondria in human HF. Interestingly, T3 up-regulated COX1 IR only at high concentrations while all administrated T4 concentrations significantly enhanced COX1-IR significantly.
3.9 Deiodinases types 2 (D2) and 3 (D3) are transcribed by human HFs

In the current study, both T4 and T3 exerted (partially differential!) effects on TH-treated human HFs. This already strongly suggested that T4 can indeed be transported into human HF cells in organ culture and is here intracellular deiodinated to T3. In order to further probe this hypothesis, we finally determined by RT-PCR whether deiodinase 2 (D2) (which transforms T4 into T3 by outer ring deiodinisation), and/or deiodinase 3 (D3) (which transforms T4 into inactive, reverse T3) (Köhrle 2000) are transcribed in micro dissected human scalp HFs.

As shown in Fig. 3.10, both deiodinases (D2 and D3) are indeed transcribed in micro dissected human HFs derived from three different individuals at the expected bp length (D2: 619 bp, D3: 292 bp).

![Figure 3.10 Micro dissected human anagen VI hair follicles express deiodinases type 2 (D2) and 3(D3)](image)

Hair follicles from three different female patients (HF 1-3) were micro dissected, mRNA extracted and analysed by semi-quantitative RT-PCR. GAPDH served as housekeeping gene. M: DNA Standard.
4 Discussion

The specific questions that this study has addressed (see Introduction, p. 41), can be answered as follows:

1. TH do alter key parameters of human HF growth and pigmentation in vitro, and namely prolong anagen (Fig. 3.4) and stimulate follicular melanogenesis while hair shaft elongation is not significantly altered.

2. Congruently, TH inhibit apoptosis, and T4 also promotes proliferation of human hair matrix keratinocytes in situ (Fig. 3.1 & 3.2).

3. In line with their anagen-prolonging effects, TH inhibit the intrafollicular expression of the key catagen-inducing growth factor TGFβ2.

4. There are subtle differences between T3 and T4 in terms of modulation of human hair growth in organ culture, since only T4 but not T3 stimulates hair matrix keratinocytes proliferation. However, pigmentation is enhanced by both T3 and T4, with T4 showing the strongest melanogenic effect.

5. Human HFs do transcribe the deiodinases type 2 and 3.

6. TH alter the expression of cytokeratin 6 and 14 in a differential manner: CK6 is up regulated, while CK14 is down regulated by both T3 and T4.

7. T3 up regulated the expression of EPO by human scalp HFs in vitro.

8. TH may alter human HF mitochondrial metabolism, since they enhance the intrafollicular immunoreactivity for COX1, a key respiratory chain enzyme.

Following in the footsteps of Billoni et al (2002), who had already demonstrated TH receptor transcript- and protein expression in human HFs (namely, of TRβ2), this study provides the first comprehensive and conclusive evidence that these TH receptors are functional, and shows that human scalp HFs are indeed direct target organs for stimulation by THs. It shows that, in the absence of confounding systemic, neural, or undefined endocrine stimuli, T3 and T4 modulate multiple important parameters of normal HF biology, ranging from HF keratinocyte proliferation, apoptosis and keratin expression via HF cycling to HF pigmentation. Previously, it had already been shown that human HFs are capable of incorporating iodine in vivo: treatment of patients with radioactive iodine (I^{131}) that had undergone total thyroidectomy resulted in an accumulation of I^{131} in the scalp hair (Bhargava and Choi 2006).
In the current study, human HFs were obtained from temporal and occipital scalp skin sections of 7 different healthy donors. The donors were euthyroid (including one donor with slightly elevated TG-levels) to exclude pre-experimental changes in the donors’ HFs that might have been caused by an altered thyroid status. Unfortunately, from one donor blood values were unavailable, so no investigations could be done regarding his thyroid status. The donor with slightly elevated TG-levels was included in this study, since the levels were just slightly above the normal range, and since all other thyroid investigations were normal (no thyroid disease was documented). The additional examination of anti-thyroid-antibodies like thyroid-peroxidase (TPO) (Kopp 2005) or TSH-receptor antibodies (Fekete and Lechan 2007) would have been optimal, but could not be performed for reasons of insufficient funding. Evaluating these antibodies would have excluded autoimmune thyroid disease. This might have been beneficial in the donor with slightly elevated TG levels, but since TSH-, fT3-, fT4- and TG-levels sensitively indicate thyroid disease, the available data make it highly likely that almost all the investigated HFs were derived from euthyroid donors (Molina 2006, Brent 2008, Kopp 2005). The various quality controls that were performed (see p. 48 - 55), furthermore, ensured that all HFs employed for the current study were of sufficient biological quality.

One major challenge that arises from the current study is to, now, study clinically in hypo- and hyperthyroid patients whether altered TH-serum levels in vivo modulate HF growth, cycling, and/or pigmentation and whether these could be restored by adjusting TH-serum levels to the in vivo-HF characteristics of the euthyroid state. Clinical investigations should also assess if TH (in hypothyroidism) or TH-inhibitors (in systemic hyperthyroidism) applied topically to the human scalp induce HF alterations in vivo that correspond to those observed here in organ culture. Certainly, the current novel findings strongly encourage such clinical follow-up-trials, ideally by the use of modern phototrichogram technology for the accurate in vivo-quantification of hair shaft elongation and HF cycling over extended time periods (Gassmueller et al. 2009).
Following the lead of Billoni et al. (Billoni et al. 2000), T3-concentrations of $10^{-12}$, $10^{-10}$ and $10^{-8}$ mol L$^{-1}$ were used in this study, which cover the effective concentration that these authors had reported to promote “HF survival” of Billoni et al. in addition to slightly infra- and supraphysiological concentrations. For T4, a physiological concentration of $10^{-7}$ mol L$^{-1}$ was applied as well as infra- ($10^{-8}$ mol L$^{-1}$) and supra- ($10^{-6}$ mol L$^{-1}$) physiological concentrations (Eisenberg et al. 2008, Larsen et al. 2007). Thus, a wide range of TH-concentrations was employed to cover the possibilities of both higher and lower hormone uptake in organ culture compared to the *in vivo*-conditions. Systematic studies with an extended dose range would have revealed further insights into the dose-dependency of the effects examined, but could not be performed since this would have required a much larger number of donors and HFs than was available for this study.

Furthermore it needs to be kept in mind that the concentrations referred to as “physiological” are those of free T3 and free T4 measured in human serum, and do not necessarily reflect the actual TH concentration present in peripheral target tissues such as in normal human skin and its appendages *in vivo* (this concentration remains unknown). Since *in vivo* TH reach the HF via its dense vasculature, namely via the well-perfused CTS and the dermal papilla, *in vitro* TH-uptake into the HF occurs only through diffusion and not perfusion. Therefore, one can assume that higher TH-concentrations are necessary in organ culture in order to generate the same intrafollicular T3/T4 levels *in vitro* as the human HF is exposed to *in vivo*. Since the study focussed on exploring whether there are any direct effects of TH on human HFs at all, enzymes that control TH-uptake, such as MTC8 and MTC10 (van der Deure et al. 2010) were not specifically studied. It will be interesting to investigate in follow-up studies where exactly these enzymes are expressed in the human HF, and whether their activity changes during HF cycling and after exposure to substrate (i.e. different concentrations of T3 or T4).

To investigate the effects of TH on human HFs, previously developed standard techniques of quantitative immunohistomorphometry were used, based on highly sensitive and specific immunohistochemistry and immunofluorescence methods (Foitzik et al. 2006, Bodó et al. 2007a+b, Ito et al. 2005). For the assessment of erythropoietin-IR, the highly sensitive EnVision® visualization technique (Bodó et
al. 2007a) was employed, while the even more sensitive TSA-immunostaining method was used to investigate TGF-β2 immunoreactivity in the proximal ORS. Since all immunostainings were performed with adequate negative and positive control (see table 2.4), which yielded the expected results, this attested to the sensitivity and specificity of the observed immunoreactivity patterns.

While the paucity of available human scalp HF precluded systematic dose-response studies, our findings suggest that the predominant direct effect of both physiological and supraphysiological T3 and/or T4 concentrations in human hair growth control is that of a hair growth-promoting agent:

- T4 stimulates hair matrix keratinocyte proliferation (Fig. 3.1, Fig.3.2),
- Matrix keratinocyte apoptosis is inhibited by T3 and T4 (Fig. 3.1, Fig.3.2),
- TH prolong anagen duration (i.e. retard spontaneous catagen development) (Fig. 3.4).

This makes the topical application of TH (e.g. of thyroxin in an alcoholic vehicle, just as it is regularly being practised already in clinical dermatology for other steroid hormones, such as glucocorticoids and estrogens) and attractive candidate to be tested as hair growth-stimulatory agent in the human system. The fact that topical TH has already been shown to promote pelage hair growth in mice in vivo (Safer et al. 2001) further encourages one to pursue the current preclinical data in appropriately controlled, double-blind, prospective, randomized clinical trials.

These preclinical data help to explain the previously unclear pathogenesis of the telogen effluvium observed in hypothyroid patients, where a relative TH deficiency had been proposed (but never conclusively demonstrated) to cause premature catagen induction and reduced hair matrix proliferation (Freinkel and Freinkel 1972, Eblerg 1991, Schell et al. 1991). The demonstration of the fact that the addition of exogenous TH to human HFs that are cultured in the absence (!) of TH prolongs anagen, stimulates hair matrix keratinocyte proliferation and inhibit their apoptosis provides the first direct evidence for the validity of this old postulate. These findings also correspond well to the reportedly increased hair matrix proliferation in hyperthyroid patients in vivo (Schell et al. 1991). The anagen prolongation documented here also may correspond to the (poorly defined and
unclear) parameter of “prolonged HF survival” previously reported by Billoni et al. (2000).

The stimulatory effects of T4 on human hair matrix keratinocyte proliferation stand in striking contrast to that of other steroid hormones. Both 17β-estradiol (E2) and prednisolone (P) enhance apoptosis and inhibit the proliferation of hair matrix keratinocytes in situ (in high concentrations) (Bodó et al. 2007b) possibly driving chemotherapy-damaged human HFs into “dystrophic catagen” (Bodó et al. 2009a). Also, topical E2, calcitriols (vitamin D3) and glucocorticoids had all previously been demonstrated to “freeze” murine back skin HFs in telogen and to potently induce premature catagen development in vivo (Reichrath et al. 1994, Paus et al. 1994, Ohnemus et al. 2006). Thus, it deserves to be systematically followed-up, whether topically applied THs may actually be exploited as a stimulator of human hair growth, e.g. in patients suffering from chemotherapy-induced effluvium and alopecia (Bodó et al. 2007b, Safer et al. 2009).

Interestingly, the hair growth promoting effects of TH were not associated with significant stimulatory effects of either T3 or T4 on hair shaft growth during the experimental observation period. While this correlates well with the previous results of Billoni et al. (2000), it is conceivable that the relatively short culture period may not have allowed detecting subtle TH effects on human hair shaft formation in vitro.

In this context, it needs to be kept in mind that the assay employed here creates a severely “hypothyroid” state in vitro, since HF organ culture is performed with serum-free William’s E medium supplemented only with insulin and hydrocortisone (Philpott et al. 1990). Thus, HFs could only have been stimulated by residual quantities of endogenous TH that had already been bound within the HFs (e.g. to intrafollicular TRβ) before HF micro dissection and organ-culture. With every change of medium, these residual TH quantities would have been further reduced/diluted. Therefore, it is a striking fact that, even in the absence of extra follicular TH, hair shaft production of organ-cultured, amputated human anagen VI HFs in vitro progresses at almost the normal speed compared to hair shaft growth seen in vivo (Philpott et al. 1994), just as can be seen here in the vehicle-treated control
groups (Fig. 3.3 A+B, Fig. 3.4). This suggests that, despite the profound modulatory effects of TH on several hair biology parameters demonstrated here, extra follicular TH seem dispensable for normal hair shaft production under assay conditions and for a limited time period. Naturally, this does not exclude a long-term role for TH in human hair shaft production in vivo, especially since hair shaft abnormalities have been clinically reported in both hypo- and hyperthyroid patients (Messenger et al. 2000, Fistarol 2002, Stüttgen 1974). This fact combined with a slight tendency towards enhanced hair shaft production seen in some TH-treated groups raises the possibility that, over weeks and months, TH might well be indispensable for normal hair shaft production of human scalp HFs in vivo.

Our study shows that TH do prolong anagen duration significantly in vitro, and thus demonstrates one key mechanism for how these steroid hormones may promote hair growth. This finding not only helps to explain the telogen effluvium that can be clinically observed in states of thyroid hormone deficiency (Schell et al. 1991), but also further encourages one to explore topical THs as clinically useful anti-hair loss agents.

Unfortunately, isolated human scalp anagen VI hair bulbs do not run through full cycles in organ-culture and decay shortly after catagen development (Foitzik et al. 2005, Philpott et al. 1990, Philpott et al. 1994, Ito et al. 2005). Therefore, the current organ culture assay cannot clarify another old, as yet unconfirmed hypothesis that hyperthyroidism may also lead to telogen effluvium due to the induction of faster hair follicle cycling (Messenger 2000, Fistarol 2002, Everett et al. 1997, Kaminski 1997). In the current study, high concentrations of T3 or T4 even prolonged anagen duration compared to control (Fig. 3.4). This questions the validity of the old hypothesis of faster HF cycling induced by TH in hyperthyroidism. However, the multiple endocrine changes induced by hyperthyroidism in vivo and potential concomitant effects of anti-thyroid auto antibodies (e.g., anti-TSH receptor auto antibodies might stimulate keratinocyte proliferation [Cianfarani et al. 2010]) require caution against overly simplistic transfer of the current in vitro data to the much more complex clinical situation in hyperthyroid patients. Also, the possibility deserves to be considered that the effluvium observed in hyperthyroid patients (Fistarol 2002) might speculatively
reflect TH-induced excessive stimulation of active hair shaft shedding (exogen).
Since, unfortunately, there is no assay for studying exogen in organ-cultured human HFs available yet, this intriguing theoretical possibility could not be excluded or verified here.

The current study provides at least one important pointer to the molecular mechanisms by which TH may exert their anagen-prolonging effects: TH down-regulate the intra-follicular protein expression of TGFβ2 (Fig. 3.5), one of the recognized key catagen inducers during human HF cycling, which also inhibits proliferation and stimulates apoptosis of human hair matrix keratinocytes in situ and operates as the key terminator of anagen (Hibino and Nishiyama 2004, Itami and Inui 2005, Soma et al. 2002). Despite substantial inter-individual variations, a tendency towards suppression of TGFβ2 could be identified in all HFs investigated here. Although this down-regulatory effect of TH on TGFβ2 may only reflect a small segment of the changes induced by TH in the complex intrafollicular signalling milieu that drive HF transformations from anagen VI towards catagen (see introduction) its inhibition by TH constitute at least one concrete and likely molecular mechanism of TH-action.

The inhibition of intra-follicular TGFβ2 expression by TH is in striking contrast to that of another important, hair growth-modulatory steroid hormone, i.e. alltrans-retinoic acid (tretinoin): It had previously been shown that tretinoin exerts its hair growth-inhibitory, catagen-promoting effects on organ-cultured human HFs at least in part via up-regulating TGFβ2 (Foitzik et al., 2005). While alltrans-retinoic acid is another important, hair growth-modulatory steroid hormone (Foitzik et al., 2005), one of its nuclear hormone receptors (RXR) is a known heterodimerization-partner of the thyroid hormone receptor (TR) (Leid et al. 1992). Thus, it is conceivable that RXR and TR ligands interact in the control of HF cycling so as to fine-tune the switch from anagen to catagen by impacting on the intrafollicular TGFβ2 level.

An extended analysis of how TH alter the intra-follicular transcription and protein expression for TGFβ2 is an obvious next step for follow-up studies. Also, it remains to be demonstrated that down-regulation of TGFβ2 is really needed for the anagen-prolonging effects of TH. This could be achieved e.g. by showing that
the latter effects can be abrogated by the co- administration of TGFβ2- neutralizing antibodies (just as it has already been documented for the TGFβ2- dependence of catagen- promoting effects of retinoids [Foitzik et al. 2005]), or by the knock-down of TGFβ2 or TGFβ receptor type II by siRNA technology (e.g. Elbashir et al. 2002) in the presence of TH stimulation.

The current study also revealed for the first time that TH modulate the intrafollicular protein expression for two recognized thyroid hormone-responsive keratins, namely CK6 and CK14 in situ (Fig. 3.6). Since the promoter regions of these keratin genes host TREs it is conceivable that TH-TR complexes regulated the transcription of these keratin genes via the classical, TRE-dependent nuclear pathway (Radoja et al. 1997, Freedberg et al. 2001, Blumenberg et al. 1992). In skin, specific keratins can be employed to distinguish between defined keratinocyte subpopulations. For example, cytokeratins 5 and 14 characterize proliferating basal layer keratinocytes, while the cytokeratins 1 and 10 are expressed in terminally differentiating human epidermal keratinocytes (Freedberg et al. 2001). In response to injury (wound healing) or under pathologic conditions (e.g. inflammation-associated hyperproliferation) the keratinocytes can express CK6, CK16, and CK17 (Tomic-Canic et al. 1998, Langbein and Schweizer 2005). Our study showed that TH enhance protein expression of the type II keratin, CK 6, which typically expressed by proliferating ORS keratinocytes under physiological conditions, and decreased expression of the type I keratin, CK 14, which characterizes all proliferating keratinocyte populations in the epidermis and HF (Langbein and Schweizer 2005).

While the current study does not allow drawing definitive conclusions on the functional importance of the regulation of these keratins by TH, it is conceivable that TH modulate ORS keratinocytes functions. The stimulatory effect of TH on CK6 expression may be interpreted to be in line with the concept that this keratin, generally, is thought to be associated with hyperproliferative states of human skin epithelium (Ramot et al. 2009, Langbein and Schweizer 2005). However, the proliferation- stimulatory TH effects on hair matrix keratinocytes in situ seem to conflict with the simultaneous down- regulation of the prototypic keratin of proliferating, basal layer keratinocytes, CK14. However, the expression of both
keratins was measured in the ORS far above (i.e. distal to) the hair matrix, while proliferation was only measured in hair matrix keratinocytes (i.e. in a biologically very different, much less differentiated HF keratinocyte population), these results are not necessarily conflicting: A down-regulatory effect on basal ORS keratinocyte CK14 expression does not exclude a proliferation-stimulatory effect of TH in the hair matrix. Future studies should follow-up the intriguing differential effects of TH on CK6 versus CK14 in all epithelial skin compartments that express both keratins under physiological or pathological conditions.

Also, it remains to be investigated to which extent TH alter the expression of keratins that are primarily or exclusively expressed in the hair shaft cuticle, cortex or medulla, such as the previously defined expression of hK6irs1 in the IRS (Langbein et al. 2002) and CK15 in the bulge region (Kloepper et al. 2008). This appears important since hair shaft abnormalities have been clinically reported in both hypo- and hyperthyroid patients (Messenger 2000, Fistarol 2002, Everett et al. 1997) it is likely that keratin changes caused by TH also concern the hair shaft. However, the normal speed of hair shaft production and the normal hair shaft morphology in organ-cultured HFs suggests that TH are largely dispensable for normal hair shaft production under assay conditions. Naturally, this does not exclude a long-term role for TH in human hair shaft production in vivo, as described above. Since optimized adaption of keratins is crucial for optimal function of human skin and its appendages, TH-mediated changes in keratin-expression could contribute to the environmentally adapted regulation of certain keratins (Ramot et al. 2009). This hypothesis remains to be tested.

The current study also provides the first conclusive evidence that T3 and T4 directly stimulate intrafollicular melanin synthesis (Fig. 3.7 A-D). Since intrafollicular melanogenesis is strictly coupled to anagen and HF pigmentation declines sharply during early anagen-catagen transformation of HFs (Slominski et al. 2005), our analysis was restricted to the comparison of anagen VI HFs between test and control groups. The ruled out any confounding influence hair cycle-associated pigmentation changes by TH and excluded the “stimulation” of melanogenesis only reflected the anagen-prolonging effects of TH. Although TH have been proposed for decades to be relevant for hair colour maintenance (e.g.
Lerner 1971), the current results actually provide the first evidence that TH can really stimulate melanogenesis in the mammalian system *in situ*. This correlates nicely with a recent clinical case report that *in vivo*-exposure to high doses of exogenous T4 caused darkening of gray/white hair (Redondo et al. 2007). While in this report indirect modes of TH action could not be ruled out, our data show that TH directly impacts on human HF pigmentation. Naturally, this suggests that topically applied TH might become a new clinical tool to fight hair greying (Slominski et al. 2005).

The current observation that THs appeared to even stimulate HF melanocyte dendricity (Fig.3.7 B2, C2, D2), even though the employed histochemistry method was insufficiently sensitive to confirm this, suggests that not only melanogenesis as such, but also the transfer of melanosomes from HF pigmentary unit melanocytes to terminally differentiating keratinocytes of the precortical hair matrix is stimulated by TH. If true, this would imply a far-reaching general activation of melanocytes by TH. Therefore, this interesting preliminary observation deserves to be systematically followed up, namely by immunohistochemical analysis of the expression of a key premelanosome marker, gp100 (NKi-beteb), which allows to validate the important hypothesis that THs stimulate melanosome transfer from human HF melanocytes to human HF keratinocytes *in situ* (Singh et al. 2008, Kloeppper et al. 2009). While the underlying mechanism(s) and intracellular pathways remain to be dissected, this further illustrates how well-suited organ-cultured human scalp HFs are as a clinically relevant, highly instructive, yet still underexploited discovery tool for the identification of new functions for ancient steroid hormones in cutaneous endocrinology.

As discussed, thyroid diseases can induce distinct hair phenotypes in affected patients (see Introduction, p. 38-39). Since most of the endogenous TH is available as T4 in the serum, while the form considered to be the biologically more "active" one is T3 (Molina 2006), conventional wisdom holds that deiodinases are necessary to convert T4 into T3 within target cells. Since we show here that, not only T3, but also T4 significantly modulates key read-out parameters of human HF biology in organ culture, it is likely that human HFs can convert T4 to T3 – just like all TH-sensitive target tissues (Köhrle 2000). Intriguingly, DIO2 mRNA was already
detected by laser capture micro dissection in the stem cell-rich bulge region of the human HF ORS (Ohyama et al. 2006), while DIO 2 and DIO 3 deiodinase transcripts had previously be found in cultured human skin fibroblasts, melanocytes and keratinocytes (Slominski et al. 2002) and in cultured K15+ human epithelial progenitor cells (Tiede et al. 2009). This corresponds well to the current finding that human HFs transcribe deiodinase genes (Fig. 3.10) and further supports the concept that human HFs have the enzymatic equipment to convert T4 into T3.

The recent finding that human HF epithelial stem cells show an unusually high transcription of deiodinases in situ and in cell culture (Ohyama et al. 2006, Tiede et al. 2009) raises the important question whether these crucial epithelial stem cells of human skin are particularly sensitive to TH stimulation, namely by T4, and which stem cell functions are modulated by TH stimulation. Luckily, the most recent establishment of keratin 15 promoter-driven GFP+ human epithelial hair HF progenitor cells (Tiede et al. 2009) offers a powerful new research tool to directly investigate the role of TH in the as yet obscure hormonal controls of HF stem cells (Paus et al. 2008).

The subtle differences observed here between T3 and T4 in the assessed parameters, namely with respect to HF proliferation and HF pigmentation (see e.g. Figs. 3.1, 3.2 and 3.7), raise the possibility that T4 also unfolds separate activities that are independent of its conversion to T3 (Davis et al. 2005). In this context, it is particularly interesting that only T4 stimulated hair matrix keratinocyte proliferation significantly in these experiments, but not T3. This makes it unlikely that the observed T4 effects were mainly due to intrafollicular conversion of T4 to T3 e.g. by DIO2. Instead, this finding might be interpreted as an indication that T4 acts directly on the HF epithelium via cytosolic activation of the IP3- (Davis et al. 2008) or the MAP-kinase (Lin et al. 1999) pathways (see below). However, in the higher concentrations of T3 tested, there was a tendency towards the stimulation of hair matrix proliferation, which might have reached significance if a higher number of HFs could have been tested. Thus, at least some of the observed TH effects likely were mediated by T3, which has a much higher affinity to TRβ2 than T4 (Molina 2006). A deiodinase- inhibitor (iopanoic acid = IOP), which inhibits deiodinases 1 and 2, was shown to suppress the proliferation of primary cultured human
keratinocytes. This effect could be counteracted by application of T3 but not by T4, suggesting that T3 is the main regulator for human epidermal keratinocyte proliferation in vitro (Safer et al. 2009). Instead, our data question whether this concept is also valid for human hair matrix keratinocytes in situ, and raise the intriguing possibility that this cell population primarily relies on T4 to regulate its proliferation in vivo.

Given the many direct TH target genes that display a TRE in their promoter region and the numerous additional negative TRE regulated genes that nevertheless are regulated by TH (Shen et al., 2004) as well as non-classical, receptor-independent TH activities (Davis et al. 2005, Davis et al. 2008) (see table 4.1), multiple additional pathways and molecular targets by which TH may impact on human HF biology must now be considered and systematically explored.

<table>
<thead>
<tr>
<th>examples</th>
<th>reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRE-dependent</td>
<td>Increased turnover</td>
</tr>
<tr>
<td>CK14 and CK6-regulation</td>
<td>Radoja et al. 1997</td>
</tr>
<tr>
<td>Negative TRE</td>
<td>TRH-regulation</td>
</tr>
<tr>
<td>Prohormone-Convertase regulation</td>
<td>Shen et al. 2004</td>
</tr>
<tr>
<td>Non-genomic</td>
<td>HIF-1α induction</td>
</tr>
<tr>
<td>Increased cardiac output and lowering of vascular resistance</td>
<td>Schmidt et al. 2002</td>
</tr>
</tbody>
</table>

*Table 4.1 different pathways of thyroid function*

For example, TRE-independent effects of TH even display immunomodulatory impact, since TH may augment IFNγ-effects via PKC and PKA (Lin et al. 1997). Also, since Lin et al. (1997) have published that T4 induces calcium signalling via direct cytosolic binding to TRβ, one reasonable focus of such future studies could be to characterize the differential impact of T4 versus T3 on intracellular calcium signalling in human HF keratinocytes in vitro. Non-genomic effects of TH might be important for the fine-tuning of HF defined functions/activities (e.g. hair cycle-dependent hair matrix keratin proliferation/apoptosis and cytokeratin expression).
The role of non-genomic, TRE-independent effects of TH could be probed under physiologically relevant conditions in the human system by stimulating organ-cultured scalp HFs with T4 in the presence of deiodinase inhibitors, or by pretreating HFs with deiodinase siRNA before T4 administration. Any alterations of HF biology read-out parameters that T4 still induces then, would likely not result from its conversion to T3 and may represent non-genomic effects. A comparison with T3 administration with the appropriate inhibitors/siRNA could clarify, whether also T3 is able to exhibit non-genomic effects.

Since hypothyroidism is frequently associated with macrocytic hypochromic anaemia of moderate severity or hyper-proliferation of immature erythroid progenitors (Larsen et al. 2008), a role for TH on haematopoiesis has long been appreciated, even though the exact underlying mechanisms, including the role of EPO in mediating TH effects on human haematopoiesis, are still debated (Kawa et al. 2009, Gianoukakis et al. 2009). Since it was recently shown that EPO is expressed on the gene and protein level by human HFs and induces differential gene expression changes in the latter (Bodó et al. 2007a), it was particularly intriguing that T3 and T4 increased the intrafollicular protein immunoreactivity for EPO in the central ORS of organ-cultured human scalp HFs (Fig. 3.8). These results are in line with previous reports that TH can stimulate EPO-expression in HepG2 cells, a human hepatoma cell line, and rat kidney (Ma et al. 2004).

In the bone marrow, EPO potently inhibits the apoptosis of erythroid progenitor cells (Jelkmann 2004). In addition, EPO is increasingly understood to operate as a general inhibitor of apoptosis in multiple different systems (Brines and Cerami 2006, Kaushansky 2006, Paus et al. 2009). Therefore, it is conceivable that TH recruit intrafollicular EPO production as yet another player in the regulation of hair matrix apoptosis (e.g. to prolong anagen by suppressing matrix keratinocyte apoptosis). However, in the current study, the up-regulatory effect of TH on EPO expression was only seen in the ORS, not in hair matrix keratinocytes, even though the highly sensitive EnVision® immunostaining technique was used. This makes it less likely that TH recruit EPO to regulate hair matrix apoptosis, and one can currently only speculate whether TH-induced EPO production in the ORS
suppresses apoptosis in human ORS keratinocytes in situ functioning e.g. as an endogenous cytoprotectant during HF cycling (Bodó et al. 2007a).

Most recent evidence suggests that EPO can also exert – albeit, greatly divergent - pigmentary effects on human HF in organ culture, as it both up- and down-regulated the melanin content and tyrosinase activity in situ in HFs derived from different donors (Bodó et al. 2009c). Although purely speculative, up regulation of EPO production in the ORS may, therefore, also indirectly affect HF pigmentation, e.g. by modulating the secretion of pigmentation-regulatory signals from the ORS. As TH not only directly enhance hypoxia-induced EPO- formation in the isolated HepG2 cells but also increase hypoxia inducible factor subunit α (HIF-1α), a key upregulator of EPO- production (Ma et al. 2004). Since HIF-1α regulation is reportedly displayed by non- genomic TH- action (Moeller et al. 2005), the exact role of TH as promoters of non-classical EPO production by peripheral tissues certainly is a fascinating new research frontier.

It has long been recognized that TH are key regulators of energy metabolism (Sheehan et al. 2004, Arnold et al. 1998, Pillar and Seitz 1997, Mutvei et al. 1989, Soboll 1993). On the cellular level, this effect appears to be mediated at least in part via up-regulation of cytochrome-c-oxidase (COX1) expression, a key respiratory chain enzyme located at the inner membrane of mitochondria (Sheehan et al. 2004, Arnold et al. 1998, Pillar and Seitz 1997, Scheffler 2008). Here, we show by quantitative immunohistomorphometry that T3 and T4 indeed up-regulate IR for COX1 in the ORS (Fig. 3.9). Functional cytochrome-c-oxidase subunit 1 is required for the stability of complex IV of the respiratory chain (Li et al. 2007). These COX1 data raise the possibility that the proliferation-stimulatory effects of T3/ T4 on human hair matrix keratinocytes (Fig. 3.1, Fig. 3.2) may reflect, at least in part, a TH-induced boosting effect on mitochondrial inner membrane potential, and ultimately the intramitochondrially generated ATP level (Gouveia et al. 2002, Scheffler 2008). Thus, another sensible follow-up experiment would be to compare the ATP levels of TH-treated and control HFs so as to further explore this hypothesis.
The current study nicely illustrates that human HF organ culture (Philpott et al. 1990) offers an excellent, physiologically and clinically relevant test system not only to elucidate this still unclear effects of TH on human hair growth and pigmentation, but also for exploring both classical and non-classical effects of TH on peripheral TH target tissues. As demonstrated here, this simple and highly instructive test system allows one to identify and explore novel functions of TH, thus complementing our – still very incomplete - understanding of the role of steroid hormones in cutaneous endocrinology.

Recently, a novel “microfolliculoid” assay system to further dissect the epithelial and mesenchymal interactions that underlie human HF biology was introduced by Havlickova et al. (2009). This assay offers an attractive research tool for characterizing and experimentally manipulating the signalling exchanges between HF keratinocytes and specialized, inductive HF fibroblasts after the TH stimulation. This assay optimally complements classical human HF organ culture and could facilitate e.g. TR overexpression and knock-down experiments to gain deeper insights into nuclear and non-nuclear effects of TH, using specific antagonists to block the different pathways (Safer et al. 2009). This “microfolliculoid” system could also reveal further insights into the regulation of the HPT-axis equivalent system that may be established in the HF itself: TSH-R was revealed to be expressed in human HF in situ. While TSH did not stimulate proliferation, pigmentation or hair growth, extrathyroidal TG- transcription occurred after stimulation with TSH in human HF (Bodó et al. 2009b), indicating that at least this element of the HPT-axis is present in normal human HFs. Additional recent evidence that human scalp HFs express both TRH and TRH-R and that TRH is a strong stimulator of human hair growth in vitro (Gáspár et al. 2009), stand alongside the most recent discovery that TRH stimulates hair matrix proliferation. There, this “microfolliculoid” system should help to further explore whether or not a fully function HPT axis equivalent (Paus 2010) is really established in normal human HFs.
5 Summary

Clinically, insufficient as well as excess levels of thyroid hormones (T3 and T4) can result in modification of hair structure and function and can lead to effluvium or even alopecia. Whether T3 and T4 exert any direct effects on human hair follicles (HFs), and if so, how exactly human HFs respond to T3/T4 stimulation, is still unclear. Therefore, the impact of T3/T4 on human HF in vitro was investigated in this study. To this aim, human anagen HFs were micro dissected from skin obtained from euthyroid females (40-69 yrs) undergoing routine facelift surgery, and were treated with T3/T4 or vehicle as control in serum-free organ culture.

Here the study shows that T4 up-regulates the proliferation of hair matrix keratinocytes, whereas their apoptosis is down-regulated by T3 and T4 in organ-cultured normal human scalp HFs. Furthermore, T4 prolongs the duration of anagen, the hair growth phase, in vitro. This anagen- prolongation may due to the down-regulation of TGF β2, the key anagen- inhibitory growth factor. Intrafollicular immunoreactivity for the recognized thyroid hormone-responsive keratins cytokeratin 6 (CK6) and cytokeratin 14 (CK14) is significantly altered by T3 and T4 (CK6 is enhanced, CK14 down regulated). Both T3 and T4 also significantly stimulate intrafollicular melanin synthesis, with supraphysiological concentrations of T4 showing the strongest stimulation of intrafollicular melanogenesis. Since thyroid hormones reportedly can stimulate erythropoietin expression and since previously human scalp HFs were identified as an extrarenal source of erythropoietin, it was also assessed whether thyroid hormones increase intrafollicular erythropoietin immunoreactivity. This is indeed the case. In addition, T3 and T4 also up-regulate the expression of cytochrome-c-oxidase subunit I (COX1), a key respiratory chain enzyme, in the outer root sheath of the HF. Finally, both deiodinase 2 and deiodinase 3 are transcribed in the human HF, thus allowing a intrafollicular transformation of T4 into T3.

Taken together, this study present the first evidence that human HFs are direct targets of thyroid hormones and that T3 and/or T4 modulate multiple, clinically important hair biology parameters, ranging from HF cycling to hair pigmentation.
6 Zusammenfassung


dem Abbau der Schilddrüsenhormone auch die Konversion von T4 zu T3 möglich ist.
Zusammengefasst präsentiert diese Studie also den ersten Beweis, dass humane HF direkte Zielstrukturen für Schilddrüsenhormone darstellen und demonstriert, dass T3 und/oder T4 multiple Parameter der Haarbiologie vom Haarzyklus bis zur Pigmentation beeinflussen.
7 References

Ahsan MK, Urano Y, Kato S, Oura H, Arase S

Aoki H, Yamada Y, Hara A, Kunisada T

Aranda A and Pascual A
Nuclear hormone receptors and gene expression. Physiol Rev 81, 1269-1304 (2001).

Arnold S, Goglia F, Kadenbach B

Aspengren S, Hedberg D, Sköld HN, Wallin M

Banba K, Tanaka N, Fujioka A, Tajima S

Barbosa AJ, Castro LP, Margarida A, Nogueira MF

Bhargava P and Choi WS

Billoni N, Buan B, Gautier B, Gaillard O, Mahe YF, Bernard BA

Bizhanova A and Kopp P

Blumenberg M, Connolly DM, Freedberg IM

Brent GA

Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin. FASEB J 12, 3346–3354 (2007)a.

Bodó E, Tobin DJ, Kamenisch Y, Biró T, Berneburg M, Funk W, Paus R
Bodó E, van Beek N, Naumann V, Ohnemus U, Brzoska T, Abels C, Paus R

Bodó E, Kromminga A, Biró T, Borbiró I, Gáspár E, Zmięwski MA, van Beek N, Langbein L, Slominski AT, Paus R


Botchkarev VA, Botchkareva NV, Albers KM, van der Veen C, Lewin GR, Paus R

Botchkarev VA, Botchkareva NV, Albers KM, Chen LH, Welker P, Paus R


Botchkarev VA and Paus R

Botchkarev VA, Botchkareva NV, Peters EM, Paus R

Botchkareva NV, Khlagatian M, Longley BJ, Botchkarev VA, Gilchrest BA

Brines M and Cerami A

Chase HB


Cotsarelis G
Cotsarelis G and Botchkarev VA

Davis PJ, Davis FB, Cody V

Davis PJ, Leonard JL, Davis FB

Dawber RP

Dawber R

Demirkesen C, Hoede N, Moll R

Deplewski D, Rosenfield RL

Dermatlas
www.dermatlas.org – specific page: http://dermatlas.med.jhmi.edu/derm/ (day of visit: 5.11.2009)

Dillmann WH


Dunn JT and Dunn AD
The importance of thyreoglobuline structure for thyroid hormone biosynthesis. Biochimie 81, 505-509 (1999).

Ebling F


Eisenberg M, Samuels M, DiStefano JJ 3rd.
Extensions, validation, and clinical applications of a feedback control system simulator of the hypothalamo-pituitary-thyroid axis. Thyroid 18, 1071-1085 (2008).
Elbashir SM, Harborth J, Weber K, Tuschl T

The transcriptional repressor CDP (Cutl1) is essential for epithelial cell differentiation of the lung and the hair follicle. Genes Dev. 17, 2307–2319 (2001).

Everett LA, Glaser B, Beck JC, Idol JR, Buchs A, Heyman M, Adawi F, Hazani E, Nassir E, Baxevanis AD, Sheffield VC, Green ED,

Fekete C and Lechan RM

Feng X, Jiang Y, Meltzer P, Yen PM
Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol 14, 947–955 (2000).

Ferguson K

Fistarol SK

Foitzik K, Spexard T, Nakamura M, Halsner U, Paus R

Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol 3, 748–756 (2006).

Foitzik K, Langan EA, Paus R

Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M

Freinkel RK and Freinkel N


Gassmueller J, Rowold E, Frase T, Hughes-Formella B
Gérard A, Many M, Daumerie C, Costagliola S, Miot F, DeVijlder JJM, Colin IM, Denef J


Gouveia CH, Schultz JJ, Jackson DJ, Williams GR, Brent GA
Thyroid hormone gene targets in ROS 17/2.8 osteoblast-like cells identified by differential display analysis. Thyroid 8, 663–671 (2002).

Gu LH and Coulombe PA

Gymfi C, Wapner RJ, D’Alton ME

Hale PA and Ebling FJ

Handjiski BK, Eichmüller S, Hofmann U, Czarnetzki BM, Paus R

Hashimoto H


Headington JT

Hibino T and Nishiyama T

Higgins CA, Westgate GE, Jahoda CA

Hollenberg AN, Monden T, Flynn TR, Boers ME, Cohen O, Wondisford FE
The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements. Mol Endocrinol 9, 540-550 (1995).

Itami S and Inui S

Ito T, Ito N, Saathoff M, Bettermann A, Takigawa M, Paus R
Jelkmann W

Johns SA, Soullier S, Rashbass P, Cunliffe VT

Kaminski C

Kaushansky K


Kligman AM


Kloepper JE, Sugawara K, Al-Nuaimi Y, Gáspár E, van Beek N, Paus R

Köhrle J

Köhrle J

Kopp P

Langan EA, Ramot Y, Goffin V, Griffiths CE, Foitzik K, Paus R

Langbein L, Rogers MA, Praetzel S, Aoki N, Winter H, Schweizer J
A novel epithelial keratin, hK6irs1, is expressed differentially in all layers of the inner root sheath, including specialized huxley cells (Flugelzellen) of the human hair follicle. J Invest Dermatol 5, 789–799 (2002).

Langbein L, Spring H, Rogers MA, Praetzel S, Schweizer J

Langbein L and Schweizer J

Larsen PR, Davies T, Schlumberger M, Hay I


Lerner AB


Lin HY, Yen PM, Davis FB, Davis PJ

Lin HY, Davis FB, Gordinier JK, Martino LJ, Davis PJ

Lindner G, Botchkarev VA, Botchkareva NV, Ling G, van der Veen C, Paus R

Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. Am J Physiol Regul Integr Comp Physiol 3, R600-7 (2004).

Maurer M, Peters EM, Botchkarev VA, Paus R

Active hair growth (anagen) is associated with angiogenesis. J Invest Dermatol 114, 909-916 (2000).

Messenger AG

Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 159,1077-1085.
Michelet JF, Gautier B, Gaillard O, Bernard BA, Benech F
Human hair follicle pigmentary unit as a direct target for modulators of melanogenesis, as studied by [(14)C]-2-Thiouracil incorporation. Exp Dermatol 18, 414-416 (2009).

Moeller LC, Dumitrescu AM, Refetoff S
Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1alpha and glycolytic genes. Mol Endocrinol 19, 2955-2963 (2005).

Molina PE

Mohn MP

Moore JM and Guy RK
Coregulator interactions with the thyroid hormone receptor. Mol Cell Proteomics 4, 475-482 (2005).

Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F


Mutvei A, Kuzela S, Nelson BD

Mutvei A and Nelson BD,

Nilsson M
Iodide handling by the thyroid epithelial cell. Exp Clin Endocrinol Diabetes 1, 13–17 (2001).

Nishimura EK, Jordan SA, Oshima H, Yoshida H, Osawa M, Moriyama M, Jackson IJ, Barrandon Y, Miyachi Y, Nishikawa S

Ohnemus U, Uenalan M, Inzunza J, Gustafsson JA, Paus R

Ohyama M, Terunuma A, Tock CL, Radonovich MF, Pise-Masison CA, Hopping SB, Brady JN, Udey MC, Vogel JC

Olszewska E and Sudhoff H

Oppenheimer JH and Schwartz HL
Oshima H, Rochat A, Kedzia C, Kobayashi K, Barrandon Y

Panteleyev AA, Paus R, Christiano AM
Patterns of hairless (hr) gene expression in mouse hair follicle morphogenesis and cycling. Am. J. Pathol. 4, 1071–1079 (2000).

Paris, Brunet, Markov, Schubert, Laudet

Park HY, Kosmadaki M, Yaar M, Gilchrest BA

Paschke R and Ludgate M,

Paus R, Stenn KS, Link RE

Paus R, Handjiski B, Czarnetzki BM, Eichmüller S

Paus R, Peters EM, Eichmüller S, Botchkarev VA

Paus R and Cotsarelis G

Paus R, Müller-Röver S, Botchkarev VA

Paus R and Foitzik K
In search of the "hair cycle clock": a guided tour. Differentiation 72, 489-511 (2004).

Paus R, Peker S, Sundberg JP

Paus R

Paus R, Arck P, Tiede S

Paus R, Bodó E, Kromminga A, Jelkmann W

Paus R

Pearce EN, Gerber AR, Gootnick DB, Khan LK, Li R, Pino S, Braverman LE
Peters EM, Tobin DJ, Botchkareva N, Maurer M, Paus R
Migration of melanoblasts into the developing murine hair follicle is accompanied
Philpott MP, Green MR, Kealey T
Philpott MP, Sanders D, Westgate GE, Kealey T
Philpott MP, Sanders DA, Kealey T
Pillar TM and Seitz HJ
Thyroid hormone and gene expression in the regulation of mitochondrial
Plikus MV and Chuong CM
Complex hair cycle domain patterns and regenerative hair waves in living rodents.
Plikus MV, Mayer JA, de la Cruz D, Baker RE, Maini PK, Maxson R, Chuong
CM
Cyclic dermal BMP signalling regulates stem cell activation during hair
Poblet E, Ortega F, Jiménez F
The arrector pili muscle and the follicular unit of the scalp: a microscopic anatomy
Powell BC and Rogers GE
The role of keratin proteins and their genes in the growth, structure and properties
Radoja N, Diaz DV, Minars TJ, Freedberg IM, Blumenberg M, Tomic-Canic M
Specific organization of the negative response elements for retinoic acid and
thyroid hormone receptors in keratin gene family. J Invest Dermatol 4, 566–572
(1997).
S, Blumenberg M
Thyroid hormones and gamma interferon specifically increase K15 keratin gene
Ramat Y, Paus R, Tiede S, Zlotogorski A
Randall VA,
Hormonal regulation of hair follicles exhibits a biological paradox. Semin Cell Dev
Redondo P, Guzmán M, Marquina M, Pretel M, Aguado L, Lloret P,
Gorrochategui A
Repigmentation of gray hair after thyroid hormone treatment. Actas Dermosifiliogr
9, 603–610 (2007).
Reichrath J, Schilli M, Kerber A, Bahmer FA, Czarnetzki BM, Paus R
Hair follicle expression of 1,25-dihydroxyvitamin D3 receptors during the murine
Reynolds AJ, Lawrence C, Cserhalmi-Friedman PB, Christiano AM, Jahoda CA
Rook A
Rosenquist TA and Martin GR
Fibroblast growth factor signalling in the hair growth cycle: expression of the
fibroblast growth factor receptor and ligand genes in the murine hair follicle. Dev
Safer JD, Fraser LM, Ray S, Holick MF
Topical triiodothyronine stimulates epidermal proliferation, dermal thickening, and
Safer JD, Persons K, Holick MF
A thyroid hormone deiodinase inhibitor can decrease cutaneous cell proliferation in
Sainton P and Simonnet H
Ann Mid 29, 263 (1931).
Sakita S, Ohtani O, Nakatani T, Morohashi M
Three-dimensional microvasculature of the hair follicle. J Dermatol Sci 7, S1-4
(1994).
Sano S, Kira M, Takagi S, Yoshikawa K, Takeda J, Itami S
Two distinct signaling pathways in hair cycle induction: Stat3-dependent and
Sarin KY and Artandi S
Aging, graying and loss of melanocyte stem cells. Stem Cell Rev 3, 212-217
(2007).
Sawin CT, Bigos ST, Land S, Bacharach P
The aging thyroid. Relationship between elevated serum thyrotropin level and
Schallreuter K, Slominski A, Pawelek JM, Jimbow K, Gilchrest BA
Scheffler IE
Schell H, Kiesewetter F, Seidel C, von Hintzenstern J
Cell cycle kinetics of human anagen scalp hair bulbs in thyroid disorders
Schmidt BM, Martin N, Georgens AC, Tillmann HC, Feuring M, Christ M,
Wehling M
Nongenomic cardiovascular effects of triiodothyronine in euthyroid male
Schneider MR, Schmidt-Ullrich R, Paus R
Schweizer J, Langbein L, Rogers MA, Winter H
(2007)
Scott G, Leopardi S, Printup S, Madden BC
Filopodia are conduits for melanosome transfer to keratinocytes. J Cell Sci Pt 7,
Scott GA, Arioka M, Jacobs SE

Sheehan TE, Kumar PA, Hood DA

Shen X, Li Q, Brent GA, Friedman TC

Shupnik MA, Ridgway EC, Chin WW

Singer PA

Singh SK, Nizard C, Kurfurst R, Bonte F, Schnebert S, Tobin DJ


Slominski A, Tobin DJ, Shibahara S, Wortsman J

Slominski A, Wortsman J, Plonka PM, Schallreuter KU, Paus R, Tobin DJ

Slominski A, Wortsman J, Tuckey RC, Paus R

Soboll S
Thyroid hormone action on mitochondrial energy transfer. Biochim. Biophys Acta 1, 1–16 (1993).

Soma T, Tsuji Y, Hibino T

Stenn KS and Paus R

Stüttgen G

Tiede S, Kloepffer JE, Bodó E, Tiwari S, Kruse C, Paus R

Tiede S, Koop N, Kloepffer JE, Fässler R, Paus R

Telek A, Bíró T, Bodó E, Tóth BI, Borbíró I, Kunos G, Paus R

Tobin DJ, Foitzik K, Reinheckel T, Mecklenburg L, Botchkarev VA, Peters C, Paus R
The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am J Pathol 160, 1807–1821 (2002).

Tobin DJ, Gunin A, Magerl M, Handijski B, Paus R

Tobin DJ

Tomic-Canic M, Komine M, Freedberg IM, Blumenberg M

van der Deure WM, Peeters RP, Visser TJ
Molecular aspects of thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects of genetic variation in these transporters. J Mol Endocrinol 44, 1-11 (2010).

Velija-Asimi Z and Karamehic J


von Basedow CA
Exophthalmus durch die Hypertrophie des Zellgewebes in der Augenhöhle. Wochenzeitschrift für die gesamte Heilkunde 13, 14 (1840).


Wrutniak-Cabello C, Casas F, Cabello G

Yamaguchi Y and Hearing VJ

Yen PM
Physiological and molecular basis of thyroid hormone action. Physiol Rev 3, 1097–1142 (2001).
Zmijewski MA, Sharma RK, Slominski AT

Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R
7.1 Publications

The results presented in this thesis were published in part in:

Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. *J Clin Endocrinol Metab* 93, 4381–4388 (2008) (Impact Factor 5.25)

Abstracts based on data of this thesis:


Human hair follicles are direct targets for thyroid hormones: involvement in anagen prolongation, hair matrix proliferation, hair pigmentation and metabolism. *J Invest Dermatol* 128, 156-156 (2008).

Additional publications, where the methods learned during the thesis were employed by the candidate, who also contributed original data:

Bodó E, Kromminga A, Bíró T, Borbíró I, Gáspár E, Zmijewski MA, van Beek N, Langbein L, Slominski AT, Paus R.
Human Female Hair Follicles Are a Direct, Nonclassical Target for Thyroid-Stimulating Hormone. *J Invest Dermatol* 129, 1126-1139 (2009)

Bodó E, van Beek N, Naumann V, Ohnemus U, Brzoska T, Abels C, Paus R.

Ito N, Sugawara K Bodó E, Takigawa M., van Beek N, Ito T, Paus R.

Kloepper JE, Sugawara K, Al-Nuaimi Y, Gáspár E, van Beek N, Paus R.
7.2 Danksagung

Im Besonderen geht mein herzlicher Dank an…

… meinen sehr engagierten Doktorvater Prof. Dr. Ralf Paus für die Möglichkeit, in seiner Arbeitsgruppe Doktorandin zu sein, für die Vergabe eines spannenden Themas, für die Kongressaufenthalte, für die fachliche Unterstützung und das Vertrauen. Vielen Dank außerdem für die Möglichkeit in einem so international besetztem Labor arbeiten zu können - eine besondere Erfahrung.

… meine wundervolle Betreuerin und Freundin Dr. Enikő Bodó dafür, das sie jederzeit ein offenes Ohr für Fragen hatte und sich so viel Zeit genommen hat, mir immer mit Rat und Tat zu Seite zu stehen. Ich bedanke mich für das „Wegweisen“ bei der Planung der Experimente, für die tolle Erfahrung, mit ihr gearbeitet zu haben und für die Unterstützung bei allen Aspekten dieser Dissertation.

… Prof. Dr. Detlef Zilikens, dem Direktor der Klinik für Dermatologie und Venerologie am UK-SH, Campus Lübeck dafür, als Doktorandin in seiner Klinik die Forschung kennenlernen zu dürfen.

… die AG Wenzel, AG Wollenberg und AG Fischer für die Mitbenutzung der Gerätschaften und Räume, insbesondere Dr. Björn E. Wenzel für das ETA-Meeting in Leipzig, die AESF 2007 und die Ermöglichung der Messung der Schilddrüsenparameter. Vor allem aber bedanke ich mich für die vielen netten und hilfreichen Ratschläge.

… PD Dr. Bernhard Gibbs für die Vermittlung an die AG Paus und sein Engagement als Mentor.

… die MTA Astrid Becker der AG Paus für die genaue und gewissenhafte Einarbeitung sowie für eine tolle Zusammenarbeit in meiner Funktion als HIWI und für die Hilfe bei allen labortechnischen Fragen.

… Dr. Erzsébet Gáspár für die nette Unterstützung bei dieser Dissertation und die Einweisung in die Durchführung der PCR.

… die gesamte AG Paus für eine unvergleichlich gute Arbeitsatmosphäre, die Unterstützung und Geduld. Vielen Dank für eine tolle Zeit innerhalb und außerhalb des Labors und dafür, dass Ihr seid wie Ihr seid! Dank an den Laborchef Dr.
Stephan Tiede, an die TA’s Nadine Dörwald, Gabriele Scheel, Antje Winter-Keil, an meine Mitdoktoranden Nancy Ernst Annika Hanning, Benedikt Kany, Patrik Kleitzsch, Jana Knuver, Viktoria Naumann, Kim Nguyen, Christian Plate, Katrin Reithmeyer, Anne Spiegelberger und Friederike Wiersma. Herzlichen Dank an die Tierärztinnen Dr. Jennifer Klatte und Dr. Katja Meyer und für das Teilen ihrer Erfahrungen beim Verfassen der Dissertation, für ihre Ratschläge und die Freundschaft.
Vielen Dank auch an Yusur Al-Nuaimi, Ingrid Andersson, Nina Biedermann, Katrin Bohm, Janine Duchow, Dr. Vladimir Emilianov, Luetfiye Hastedt, Peter Keckeis, Dorothee und Dr. Ewan Langan, Katy Lyneau, Dr. Natalia Meier, Melea Menzinger, Dr. Burkhard Pöggeler, Dr. Yuval Ramot, Dr. Koji Sugawara, Dr. Wirach Taungjaruwai, Sai Kailash Uppalapati, Ronny Wachtel
… den großzügigen Dr. Dr. Wolfgang Funk, Chefarzt der Klinik Dr. Koslowski in München, für die unverzichtbaren, wertvollen Sendungen von menschlicher Kopfhaut sowie der zugehörigen Blutproben der Spender, ohne welche diese Arbeit nicht möglich gewesen wäre.
… die vielen anonymen Spender, die sich so großzügig bereit erklärt haben, bei einem Face-Lift die entfernte Haut sowie eine Blutprobe der Forschung zu überlassen und somit diese Dissertation erst ermöglicht haben.
… die Kollaborationspartnern PD Dr. Arno Kromminga aus dem Institut für Immunologie, klinische Pathologie, Molekulare Medizin, Hamburg und Dr. Michal A. Zmijewski sowie Prof. Andrzej Slominski aus dem Department of Pathology and Laboratory Medicine, and Center for Cancer Research, University of Tennessee, Memphis, Tennessee für die gute Zusammenarbeit an der Publikation, der Unterstützung bei den PCR-Arbeiten und die Bereitstellung von Antikörpern.
… meine Kommilitonnnen und guten Freundinnen Celine Hardenbicker und Sophie Spielmann für ihren Rückhalt und ihre so wichtigen Ansichten und Kommentare in jeder Phase der Arbeit.
… meiner lieben Schwester und meinen tollen Eltern sowie meiner Oma für ihr Verständnis, ihr Feedback und ihre volle Unterstützung nicht nur für diese Dissertation sondern in allen Lebenslagen.
… Kenneth für seine unendliche Geduld und sein Verständnis, sein großes Vertrauen in mich und für seine unersetzbare Unterstützung.
7.3 Curriculum Vitae

PERSONAL DATA

Full Name: Nina van Beek
Date of birth: 21 September 1983
Home address: Schwartauer Allee 65a
23554 Luebeck
Germany
Telephone: +49 4512021336
E-mail: nina.van.beek@medizin.uni-luebeck.de
Nationality: German & Dutch
Status: Student, unmarried

EDUCATION- STUDIES

February 2009- January 2010 clinical internships (“Praktisches Jahr”):
- department of Dermatology, University of Luebeck, Luebeck, Germany (February- June)
- department of Internal Medicine, University of Luebeck, Luebeck, Germany (June- August)
- department of Internal Medicine, Kilimanjaro Christian Medical Center, Moshi, Tanzania (August- Oktober)
- department of general surgery, Sana Kliniken Luebeck, Luebeck, Germany (Oktober- January)

October 2007 -February 2009 clinical studies at the University of Luebeck, Luebeck, Germany including elective “Neonatology”

March 2007 – September 2007 Experimental research (Thesis- experimental part) in experimental dermatology, AG Paus at the department of dermatology at the University of Luebeck, Germany

August 2006 – February 2007 4th year of medical studies (part 1) at the Rijksuniversiteit Groningen, Netherlands (as an exchange student following the ERASMUS-Programme) including:
- internal medicine, paediatrics, clinical pharmaceutics, clinical pathology, gynaecology, dermatology, urology
October 2005 – July 2006 clinical studies at the University of Luebeck, Luebeck, Germany including elective “Clinical Allergology”

August and September 2005 Physikum

October 2003 beginning of medical studies at the University of Luebeck, Luebeck, Germany

EDUCATION – SCHOOL
June 2003 Final Exam: German Abitur
1994 – 2003 secondary school Europaschule Gymnasium Schwarzenbek, Schwarzenbek, Germany
1992 – 1994 primary school Muessen, Muessen, Germany
1990 – 1992 primary school Marli, Luebeck, Germany

PRACTICAL EXPERIENCE
Since April 2007 working as a student assistant in the Laboratory of Experimental Dermatology, Dept. of Dermatology
February 2008 – March 2008 internship dermatology at the clinical department of dermatology, University of Luebeck, Germany
January 2008 internship surgery at the department of neurosurgery, University of Luebeck, Germany
October 2007 internship surgery at the department of plastic surgery, University of Aarhus, Denmark
November 2006 – December 2006 internship internal medicine at the department of nephrology, University of Groningen, Netherlands
February 2006 – March 2006 internship surgery at an ambulant surgery clinic for phlebology, Papenburg, Germany